{"DataElement":{"publicId":"2003716","version":"4","preferredName":"Infection Treatment Agent Text Name","preferredDefinition":"Text name for therapy or intervention targeting the infectious disease/condition under investigation.","longName":"INFEC_TX_AGT_NM","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2012746","version":"3","preferredName":"Treatments","preferredDefinition":"Therapy or intervention targeting the disease/condition under investigation.","longName":"TX","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2223331","version":"1","preferredName":"Protocol","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"C25320","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B105A-B8AD-27F8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2324753","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-2247-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-08-04","modifiedBy":"ONEDATA","dateModified":"2005-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5D3A856-8C7C-5EF2-E034-080020C9C0E0","latestVersionIndicator":"Yes","beginDate":"2002-07-15","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017114","version":"3.1","preferredName":"Infection Treatment Agent Text Name","preferredDefinition":"Text generic names for antimicrobial agents used to treat infection.","longName":"INFECT_AGT_TXT_NM_1","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"3","maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Sulfadiazine","valueDescription":"Sulfadiazine","ValueMeaning":{"publicId":"2575712","version":"1","preferredName":"Sulfadiazine","longName":"2575712","preferredDefinition":"A synthetic pyrimidinyl sulfonamide derivative, short-acting bacteriostatic Sulfadiazine inhibits bacterial folic acid synthesis by competing with para amino benzoic acid. It is used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sulfadiazine","conceptCode":"C29468","definition":"A synthetic pyrimidinyl sulfonamide derivative, short-acting bacteriostatic Sulfadiazine inhibits bacterial folic acid synthesis by competing with para amino benzoic acid. It is used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4CD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B6EF-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Tenofovir","valueDescription":"Tenofovir","ValueMeaning":{"publicId":"2575715","version":"1","preferredName":"Tenofovir","longName":"2575715","preferredDefinition":"A synthetic antiviral acyclic nucleotide analogue of adenosine 5-monophosphate.  Tenofovir is incorporated into human immunodeficiency viral DNA instead of the natural substrate deoxyadenosine 5-triphosphate, thereby inhibiting HIV-1 reverse transcriptase (RT), an RNA-dependent DNA polymerase, and resulting in DNA chain termination and impairment of viral replication and propagation.  This agent prevents HIV from reproducing in uninfected cells only.  Tenofovir exhibits activity against the hepatitis B virus (HBV). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tenofovir","conceptCode":"C29490","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B6F2-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Ticarcillin Disodium","valueDescription":"Ticarcillin Disodium","ValueMeaning":{"publicId":"2575719","version":"1","preferredName":"Ticarcillin Disodium","longName":"2575719","preferredDefinition":"The disodium salt form of ticarcillin, a broad-spectrum, semi-synthetic penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Similar to carbenicillin in action, ticarcillin inactivates the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation prevents the cross-linkage of peptidoglycan strands, thereby inhibiting the third and last stage of bacterial cell wall synthesis. This leads to incomplete bacterial cell wall synthesis and eventually causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ticarcillin Disodium","conceptCode":"C65205","definition":"The disodium salt form of ticarcillin, a broad-spectrum, semi-synthetic penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Similar to carbenicillin in action, ticarcillin inactivates the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation prevents the cross-linkage of peptidoglycan strands, thereby inhibiting the third and last stage of bacterial cell wall synthesis. This leads to incomplete bacterial cell wall synthesis and eventually causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4D4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B6F6-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Tobramycin","valueDescription":"Tobramycin","ValueMeaning":{"publicId":"2575720","version":"1","preferredName":"Tobramycin","longName":"2575720","preferredDefinition":"An aminoglycoside antibiotic derived from Streptomyces tenebrarius with bacteriostatic activity. Following active transport into the cell, tobramycin binds irreversibly to a specific aminoglycoside receptor on the bacterial 30S ribosomal subunit and interferes with the initiation complex between messenger RNA and the 30S subunit, thereby inhibiting initiation of protein synthesis, consequently leading to bacterial cell death. In addition, tobramycin induces misreading of the mRNA template causing incorrect amino acids to be incorporated into the growing polypeptide chain, consequently interfering with protein elongation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tobramycin","conceptCode":"C62082","definition":"An aminoglycoside antibiotic derived from Streptomyces tenebrarius with bacteriostatic activity. Following active transport into the cell, tobramycin binds irreversibly to a specific aminoglycoside receptor on the bacterial 30S ribosomal subunit and interferes with the initiation complex between messenger RNA and the 30S subunit, thereby inhibiting initiation of protein synthesis, consequently leading to bacterial cell death. In addition, tobramycin induces misreading of the mRNA template causing incorrect amino acids to be incorporated into the growing polypeptide chain, consequently interfering with protein elongation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4D5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B6F7-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Urised","valueDescription":"Urised","ValueMeaning":{"publicId":"2575722","version":"1","preferredName":"Urised","longName":"2575722","preferredDefinition":"A combination preparation of methenamine, methylene blue, benzoic acid, phenyl salicylate, atropine sulfate, and hyoscyamine sulfate, with anti-inflammatory, antispasmodic and analgesic properties. Methenamine hydrolyzes into formaldehyde in acidic urine, thereby providing mild antiseptic effect. Methylene blue also exerts mild antiseptic activity and may inhibit bacterial proliferation. Benzoic acid exerts mild antibacterial and antifungal activities and helps maintain an acidic pH in the urine necessary for the degradation of methenamine to formaldehyde. Phenyl salicylate exerts mild analgesic, antipyretic and anti-inflammatory actions. Atropine sulfate and hyoscyamine sulfate are antimuscarinic agents that prevent smooth muscle spasms by antagonizing actions of acetylcholine. Urised is used for the relief of symptoms associated with urinary tract infections or diagnostic procedures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atropine/Hyoscyamine/Methenamine/Methylene Blue/Phenyl Salicylate/Benzoic Acid","conceptCode":"C29532","definition":"A combination preparation of methenamine, methylene blue, benzoic acid, phenyl salicylate, atropine sulfate, and hyoscyamine sulfate, with anti-inflammatory, antispasmodic and analgesic properties. Methenamine hydrolyzes into formaldehyde in acidic urine, thereby providing mild antiseptic effect. Methylene blue also exerts mild antiseptic activity and may inhibit bacterial proliferation. Benzoic acid exerts mild antibacterial and antifungal activities and helps maintain an acidic pH in the urine necessary for the degradation of methenamine to formaldehyde. Phenyl salicylate exerts mild analgesic, antipyretic and anti-inflammatory actions. Atropine sulfate and hyoscyamine sulfate are antimuscarinic agents that prevent smooth muscle spasms by antagonizing actions of acetylcholine. Urised is used for the relief of symptoms associated with urinary tract infections or diagnostic procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B6F9-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Valganciclovir","valueDescription":"Valganciclovir","ValueMeaning":{"publicId":"2575724","version":"1","preferredName":"Valganciclovir","longName":"2575724","preferredDefinition":"A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valganciclovir","conceptCode":"C2629","definition":"A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4D9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2018-03-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B6FB-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Vancomycin","valueDescription":"Vancomycin","ValueMeaning":{"publicId":"2575725","version":"1","preferredName":"Vancomycin","longName":"2575725","preferredDefinition":"A branched tricyclic glycosylated peptide with bactericidal activity against most organisms and bacteriostatic effect on enterococci. At a site different from that of penicillins and cephalosporins, vancomycin binds tightly to the D-alanyl-D-alanine portion of cell wall precursors, thereby interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins that destroy the cell wall by lysis. Vancomycin may also alter the permeability of bacterial cytoplasmic membranes and may selectively inhibit RNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vancomycin","conceptCode":"C925","definition":"A branched tricyclic glycosylated peptide with bactericidal activity against most organisms and bacteriostatic effect on enterococci. At a site different from that of penicillins and cephalosporins, vancomycin binds tightly to the D-alanyl-D-alanine portion of cell wall precursors, thereby interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins that destroy the cell wall by lysis. Vancomycin may also alter the permeability of bacterial cytoplasmic membranes and may selectively inhibit RNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4DA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B6FC-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Voriconazole","valueDescription":"Voriconazole","ValueMeaning":{"publicId":"2575726","version":"1","preferredName":"Voriconazole","longName":"2575726","preferredDefinition":"A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. (NCI04).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Voriconazole","conceptCode":"C1707","definition":"A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2017-05-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B6FD-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"3TC","valueDescription":"3TC (Lamivudine)","ValueMeaning":{"publicId":"2576885","version":"1","preferredName":"3TC (Lamivudine)","longName":"2576885","preferredDefinition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamivudine","conceptCode":"C1471","definition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F962-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"REEVESD","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9869-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Abacavir","valueDescription":"Abacavir","ValueMeaning":{"publicId":"2575647","version":"1","preferredName":"Abacavir","longName":"2575647","preferredDefinition":"A synthetic carbocyclic nucleoside analog.  In vivo, the activated triphosphate metabolite of abacavir is incorporated into the viral DNA instead of the natural substrate deoxyguanosine, thereby inhibiting human immunodeficiency virus (HIV) reverse transcriptase (RT) and, so, the replication of the viral DNA and infectious viral particles.  This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir","conceptCode":"C61523","definition":"A nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F48C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B6FF-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Acyclovir","valueDescription":"Acyclovir","ValueMeaning":{"publicId":"2575648","version":"1","preferredName":"Acyclovir","longName":"2575648","preferredDefinition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses.  After conversion in vitro to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acyclovir","conceptCode":"C205","definition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F48D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B700-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Adefovir","valueDescription":"Adefovir","ValueMeaning":{"publicId":"3134027","version":"1","preferredName":"Adefovir","longName":"3134027","preferredDefinition":"An acyclic nucleotide adenine analogue of adenosine monophosphate and reverse transcriptase inhibitor with potent antiviral activity against hepatitis B virus (HBV). Adefovir is activated in vivo to a diphosphate metabolite by cellular kinases. In turn, adefovir diphosphate competes with the natural substrate deoxyadenosine triphosphate (dATP) for incorporation into viral DNA by competing with the natural substrate deoxyadenosine triphosphate (dATP), leading to viral RNA-dependent HBV DNA polymerase inhibition, DNA chain termination and impairment of viral replication.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adefovir","conceptCode":"C61526","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9873-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-988B-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Amantadine HCL","valueDescription":"Amantadine Hydrochloride","ValueMeaning":{"publicId":"3134028","version":"1","preferredName":"Amantadine Hydrochloride","longName":"3134028","preferredDefinition":"The hydrochloride salt of amantadine, a synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells; furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amantadine Hydrochloride","conceptCode":"C28818","definition":"The hydrochloride salt of amantadine, a synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells; furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9896-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-98AE-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Amikacin","valueDescription":"Amikacin","ValueMeaning":{"publicId":"2575651","version":"1","preferredName":"Amikacin","longName":"2575651","preferredDefinition":"A broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically locking 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and , misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amikacin","conceptCode":"C61615","definition":"A broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically locking 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F490-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B703-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Amoxicillin","valueDescription":"Amoxicillin","ValueMeaning":{"publicId":"2576924","version":"1","preferredName":"Amoxicillin","longName":"2576924","preferredDefinition":"A broad-spectrum semisynthetic antibiotic, similar to ampicillin but more resistance to gastric acids, that inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell walls. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amoxicillin","conceptCode":"C237","definition":"A broad-spectrum, semisynthetic aminopenicillin antibiotic with bactericidal activity. Amoxicillin binds to and inactivates penicillin-binding protein (PBP) 1A located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F989-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B704-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Amoxicillin/Clavulanate Potassium","valueDescription":"Amoxicillin-Clavulanate Potassium","ValueMeaning":{"publicId":"3134029","version":"1","preferredName":"Amoxicillin-Clavulanate Potassium","longName":"3134029","preferredDefinition":"A combination of the semisynthetic broad-spectrum antibiotic amoxicillin and the beta-lactamase enzyme inhibitor clavulanate potassium. Clavulanate potassium increases the serum half-life of amoxicillin by inhibiting beta-lactamase-mediated metabolism of amoxicillin.  Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell walls.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amoxicillin-Clavulanate Potassium","conceptCode":"C1023","definition":"A combination of the semisynthetic broad-spectrum antibiotic amoxicillin and the beta-lactamase enzyme inhibitor clavulanate potassium. Clavulanate potassium increases the serum half-life of amoxicillin by inhibiting beta-lactamase-mediated metabolism of amoxicillin.  Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell walls.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-98BB-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-98D4-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Amphotericin B Liposomal","valueDescription":"Amphotericin B Liposomal","ValueMeaning":{"publicId":"2576925","version":"1","preferredName":"Amphotericin B Liposomal","longName":"2576925","preferredDefinition":"Liposome encapsulated macrolide antifungal antibiotic amphotericin B.  Amphotericin B binds to ergosterol altering cell membrane integrity with subsequent cell death.  In addition, the liposomal form has decreased side effects of conventional Amphotericin. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amphotericin B Liposomal","conceptCode":"C1738","definition":"Liposome encapsulated macrolide antifungal antibiotic amphotericin B.  Amphotericin B binds to ergosterol altering cell membrane integrity with subsequent cell death.  In addition, the liposomal form has decreased side effects of conventional Amphotericin. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B707-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Ampicillin","valueDescription":"Ampicillin","ValueMeaning":{"publicId":"2576926","version":"1","preferredName":"Ampicillin","longName":"2576926","preferredDefinition":"A broad-spectrum semisynthetic derivative of aminopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell wall. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ampicillin","conceptCode":"C239","definition":"A broad-spectrum, semi-synthetic, beta-lactam penicillin antibiotic with bactericidal activity. Ampicillin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis. Ampicillin is stable against hydrolysis by a variety of beta-lactamases, therefore, can be used in wide range of gram-positive and -negative infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B708-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Ampicillin Sodium/Sulbactam Sodium","valueDescription":"Ampicillin Sodium/Sulbactam Sodium","ValueMeaning":{"publicId":"3134030","version":"1","preferredName":"Ampicillin Sodium/Sulbactam Sodium","longName":"3134030","preferredDefinition":"A combination formulation of the sodium salts of the antibiotic ampicillin and the beta-lactamase inhibitor sulbactam with antibacterial activity. Ampicillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. The sulbactam component irreversibly binds to bacterial beta-lactamase at or near its active site, thereby interfering with substrate binding and inhibiting bacterial metabolism of penicillin and cephalosporin beta-lactam antibiotics, effectively extending their antibiotic spectrum to include many beta-lactam-resistant bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sultamicillin","conceptCode":"C28823","definition":"A combination formulation of the sodium salts of the antibiotic ampicillin and the beta-lactamase inhibitor sulbactam with antibacterial activity. Ampicillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. The sulbactam component irreversibly binds to bacterial beta-lactamase at or near its active site, thereby interfering with substrate binding and inhibiting bacterial metabolism of penicillin and cephalosporin beta-lactam antibiotics, effectively extending their antibiotic spectrum to include many beta-lactam-resistant bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-98DE-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-98F6-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Amprenavir","valueDescription":"Amprenavir","ValueMeaning":{"publicId":"2576927","version":"1","preferredName":"Amprenavir","longName":"2576927","preferredDefinition":"A synthetic antiviral agent.  As a derivative of hydroxyethylamine sulfonamide, amprenavir selectively binds to and inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amprenavir","conceptCode":"C28824","definition":"A synthetic derivative of hydroxyethylamine sulfonamide that selectively binds to and inhibits human immunodeficiency virus (HIV) protease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B70A-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Atovoquone","valueDescription":"Atovoquone","ValueMeaning":{"publicId":"2575655","version":"1","preferredName":"Atovoquone","longName":"2575655","preferredDefinition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atovaquone","conceptCode":"C28838","definition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F494-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"CURTIST","dateModified":"2010-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B70B-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Azithromycin","valueDescription":"Azithromycin","ValueMeaning":{"publicId":"3134031","version":"1","preferredName":"Azithromycin","longName":"3134031","preferredDefinition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death. [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azithromycin","conceptCode":"C28844","definition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9901-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9919-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Bacitracin","valueDescription":"Bacitracin","ValueMeaning":{"publicId":"2577723","version":"1","preferredName":"Bacitracin","longName":"2577723","preferredDefinition":"A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis. The commercial preparation is a mixture of at least nine bacitracins with bacitracin A as the major constituent. It is used topically to treat open infections such as infected eczema and infected dermal ulcers. (From Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed, p1140)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bacitracin","conceptCode":"C295","definition":"A complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall. The binding interferes with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and prevents peptidoglycan synthesis, thereby inhibiting bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B70E-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Bacitracin Zinc","valueDescription":"Bacitracin Zinc","ValueMeaning":{"publicId":"3134032","version":"1","preferredName":"Bacitracin Zinc","longName":"3134032","preferredDefinition":"The zinc salt form of bacitracin, a complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin zinc binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall, thereby interfering with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and preventing peptidoglycan synthesis which leads to cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bacitracin Zinc","conceptCode":"C28857","definition":"The zinc salt form of bacitracin, a complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin zinc binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall, thereby interfering with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and preventing peptidoglycan synthesis which leads to cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-992E-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9946-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Benzylpenicillin Sodium","valueDescription":"Benzylpenicillin Sodium","ValueMeaning":{"publicId":"3134033","version":"1","preferredName":"Benzylpenicillin Sodium","longName":"3134033","preferredDefinition":"The sodium salt form of benzylpenicillin, a semi-synthetic, broad-spectrum penicillin antibiotic with bactericidal activity. Benzylpenicillin sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penicillin G Sodium","conceptCode":"C28865","definition":"The sodium salt form of benzylpenicillin, a semi-synthetic, broad-spectrum penicillin antibiotic with bactericidal activity. Benzylpenicillin sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9951-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9969-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Caspofungin","valueDescription":"Caspofungin","ValueMeaning":{"publicId":"2577795","version":"1","preferredName":"Caspofungin","longName":"2577795","preferredDefinition":"The acetate salt of an antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Caspofungin","conceptCode":"C28910","definition":"An antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B711-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Cefaclor","valueDescription":"Cefaclor","ValueMeaning":{"publicId":"3134034","version":"1","preferredName":"Cefaclor","longName":"3134034","preferredDefinition":"A beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. Cefaclor binds to and inactivates penicillin-binding proteins (PBP) located in bacterial cytoplasmic membranes. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefaclor","conceptCode":"C28911","definition":"A beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. Cefaclor binds to and inactivates penicillin-binding proteins (PBP) located in bacterial cytoplasmic membranes. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9974-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-998C-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Cefadroxil","valueDescription":"Cefadroxil","ValueMeaning":{"publicId":"3134035","version":"1","preferredName":"Cefadroxil","longName":"3134035","preferredDefinition":"A semi-synthetic, beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefadroxil","conceptCode":"C28912","definition":"A semi-synthetic, beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9997-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-99AF-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Cefazolin","valueDescription":"Cefazolin","ValueMeaning":{"publicId":"3134036","version":"1","preferredName":"Cefazolin","longName":"3134036","preferredDefinition":"A beta-lactam antibiotic and first-generation cephalosporin with bactericidal activity. Cefazolin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefazolin","conceptCode":"C28913","definition":"A beta-lactam antibiotic and first-generation cephalosporin with bactericidal activity. Cefazolin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-99BA-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-99D2-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Cefdinir","valueDescription":"Cefdinir","ValueMeaning":{"publicId":"3134037","version":"1","preferredName":"Cefdinir","longName":"3134037","preferredDefinition":"A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefdinir's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefdinir inhibits bacterial septum and cell wall synthesis formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefdinir","conceptCode":"C28914","definition":"A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefdinir's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefdinir inhibits bacterial septum and cell wall synthesis formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-99DD-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-99F5-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Cefotaxime Sodium","valueDescription":"Cefotaxime Sodium","ValueMeaning":{"publicId":"2577797","version":"1","preferredName":"Cefotaxime Sodium","longName":"2577797","preferredDefinition":"The sodium salt form of cefotaxime.  Cefotaxime inhibits mucopeptide synthesis by binding to penicillin binding proteins, causing inhibition of bacterial cell wall synthesis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefotaxime Sodium","conceptCode":"C2328","definition":"The sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B717-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Cefoxitin Sodium","valueDescription":"Cefoxitin Sodium","ValueMeaning":{"publicId":"3134038","version":"1","preferredName":"Cefoxitin Sodium","longName":"3134038","preferredDefinition":"The sodium salt form of cefoxitin, a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. Cefoxitin sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefoxitin Sodium","conceptCode":"C28915","definition":"The sodium salt form of cefoxitin, a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. Cefoxitin sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9A00-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9A18-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Cefpodoxime","valueDescription":"Cefpodoxime","ValueMeaning":{"publicId":"2575666","version":"1","preferredName":"Cefpodoxime","longName":"2575666","preferredDefinition":"A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefpodoxime","conceptCode":"C65305","definition":"A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F49F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B719-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Cefprozil","valueDescription":"Cefprozil","ValueMeaning":{"publicId":"3134039","version":"1","preferredName":"Cefprozil","longName":"3134039","preferredDefinition":"A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefprozil's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefprozil inhibits bacterial septum and cell wall synthesis formation. [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefprozil","conceptCode":"C28917","definition":"A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefprozil's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefprozil inhibits bacterial septum and cell wall synthesis formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9A23-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9A3B-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Ceftazidime","valueDescription":"Ceftazidime","ValueMeaning":{"publicId":"2575668","version":"1","preferredName":"Ceftazidime","longName":"2575668","preferredDefinition":"A beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftazidime binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftazidime is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftazidine also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceftazidime","conceptCode":"C66868","definition":"A beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftazidime binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftazidime is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftazidine also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4A1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B71B-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Ceftriaxone","valueDescription":"Ceftriaxone","ValueMeaning":{"publicId":"2575669","version":"1","preferredName":"Ceftriaxone","longName":"2575669","preferredDefinition":"A beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceftriaxone","conceptCode":"C62020","definition":"A beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4A2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B71C-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Cephalexin","valueDescription":"Cephalexin","ValueMeaning":{"publicId":"2577802","version":"1","preferredName":"Cephalexin","longName":"2577802","preferredDefinition":"A first generation semisynthetic cephalosporin antibiotic that inhibits mucopeptide synthesis by binding to penicillin binding proteins, causing inhibition of bacterial cell wall synthesis.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cephalexin","conceptCode":"C356","definition":"A beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cephalexin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to second and third generation cephalosporins, cephalexin is more active against gram-positive and less active against gram-negative organisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B71E-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Cidofovir","valueDescription":"Cidofovir","ValueMeaning":{"publicId":"2577815","version":"1","preferredName":"Cidofovir","longName":"2577815","preferredDefinition":"A synthetic nucleotide analog with antiviral activity against cytomegalovirus (CMV).  After conversion to the active metabolite cidofovir diphosphate, cidofovir selectively inhibits CMV DNA polymerase and incorporates into the growing viral DNA chain ultimately inhibiting viral DNA synthesis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cidofovir","conceptCode":"C1600","definition":"A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD04-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B71F-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Ciprofloxacin","valueDescription":"Ciprofloxacin","ValueMeaning":{"publicId":"2577817","version":"1","preferredName":"Ciprofloxacin","longName":"2577817","preferredDefinition":"A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ciprofloxacin","conceptCode":"C375","definition":"A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD06-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B720-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Clarithromycin","valueDescription":"Clarithromycin","ValueMeaning":{"publicId":"2577826","version":"1","preferredName":"Clarithromycin","longName":"2577826","preferredDefinition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clarithromycin","conceptCode":"C1054","definition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B721-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Clindamycin","valueDescription":"Clindamycin","ValueMeaning":{"publicId":"2575671","version":"1","preferredName":"Clindamycin","longName":"2575671","preferredDefinition":"A semisynthetic broad spectrum antibiotic produced by chemical modification of the parent compound lincomycin. Clindamycin dissociates peptidyl-tRNA from the bacterial ribosome, thereby disrupting bacterial protein synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clindamycin","conceptCode":"C377","definition":"A semisynthetic broad spectrum antibiotic produced by chemical modification of the parent compound lincomycin. Clindamycin dissociates peptidyl-tRNA from the bacterial ribosome, thereby disrupting bacterial protein synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4A4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B722-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Clotrimazole","valueDescription":"Clotrimazole","ValueMeaning":{"publicId":"2577813","version":"1","preferredName":"Clotrimazole","longName":"2577813","preferredDefinition":"An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clotrimazole","conceptCode":"C381","definition":"A synthetic, imidazole derivate with broad-spectrum, antifungal activity. Clotrimazole inhibits biosynthesis of sterols, particularly ergosterol, an essential component of the fungal cell membrane, thereby damaging and affecting the permeability of the cell membrane. This results in leakage and loss of essential intracellular compounds, and eventually causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD02-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B723-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Dapsone","valueDescription":"Dapsone","ValueMeaning":{"publicId":"2577850","version":"1","preferredName":"Dapsone","longName":"2577850","preferredDefinition":"A synthetic derivative of diamino-sulfone with anti-mycobacterial and anti-malarial properties.  A structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dapsone","conceptCode":"C415","definition":"A synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. As a structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Although the exact mechanism through which dapsone exerts its anti-inflammatory activity has yet to be fully elucidated, this agent interferes with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils. Dapsone's anti-inflammatory activities may contribute to the effects seen upon topical administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD27-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B726-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Cefuroxime Axetil","valueDescription":"Cefuroxime Axetil","ValueMeaning":{"publicId":"3134040","version":"1","preferredName":"Cefuroxime Axetil","longName":"3134040","preferredDefinition":"A second generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefuroxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefuroxime inhibits bacterial septum and cell wall synthesis formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefuroxime Axetil","conceptCode":"C28918","definition":"A second generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefuroxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefuroxime inhibits bacterial septum and cell wall synthesis formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9A48-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9A60-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Delavirdine Mesylate","valueDescription":"Delavirdine Mesylate","ValueMeaning":{"publicId":"2577853","version":"1","preferredName":"Delavirdine Mesylate","longName":"2577853","preferredDefinition":"A synthetic, non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Delavirdine binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with at least two other anti-retroviral drugs, this agent has been shown to reduce HIV viral load and increase CD4 leukocyte counts in the majority of patients.  As an inhibitor of the cytochrome P450 system, delavirdine may result in increased serum levels of those co-administered protease inhibitors metabolized by the cytochrome P450 system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Delavirdine Mesylate","conceptCode":"C28974","definition":"A mesylate salt form of delavirdine, a synthetic, non-nucleoside reverse transcriptase inhibitor. In combination with other anti-retroviral drugs, this agent has been shown to reduce HIV viral load and increase CD4 leukocyte counts in patients. As an inhibitor of the cytochrome P450 system, delavirdine may result in increased serum levels of co-administered protease inhibitors metabolized by the cytochrome P450 system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD2A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B72A-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Doxycycline Calcium","valueDescription":"Doxycycline Calcium","ValueMeaning":{"publicId":"2575679","version":"1","preferredName":"Doxycycline Calcium","longName":"2575679","preferredDefinition":"The calcium salt form of doxycycline exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline Calcium","conceptCode":"C29008","definition":"The calcium salt form of doxycycline exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4AC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B72E-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Doxycycline Hyclate","valueDescription":"Doxycycline Hyclate","ValueMeaning":{"publicId":"2575681","version":"1","preferredName":"Doxycycline Hyclate","longName":"2575681","preferredDefinition":"Doxycycline in the monohydrate complex with ethanol form exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline Hyclate","conceptCode":"C29007","definition":"The hyclate salt form of doxycycline, a synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline hyclate binds reversibly to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4AE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B730-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Efavirenz","valueDescription":"(DMP-266) Efavirenz","ValueMeaning":{"publicId":"2576812","version":"1","preferredName":"(DMP-266) Efavirenz","longName":"2576812","preferredDefinition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral loads, therefore retarding or preventing damage to the immune system, and reducing the risk of developing AIDS.  Efavirenz induces activity of the cytochrome P450 system, thereby accelerating its own metabolism. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efavirenz","conceptCode":"C29027","definition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication. In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral load, retarding or preventing damage to the immune system and reducing the risk of developing AIDS. Efavirenz induces activity of the cytochrome P450 system, accelerating its own metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F919-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2012-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B732-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Erythromycin","valueDescription":"Erythromycin","ValueMeaning":{"publicId":"2576825","version":"1","preferredName":"Erythromycin","longName":"2576825","preferredDefinition":"A bacteriostatic antibiotic substance produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythromycin","conceptCode":"C476","definition":"A broad-spectrum, macrolide antibiotic with antibacterial activity. Erythromycin diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F926-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B733-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Famciclovir","valueDescription":"Famciclovir","ValueMeaning":{"publicId":"2575683","version":"1","preferredName":"Famciclovir","longName":"2575683","preferredDefinition":"A diacetyl 6-deoxy prodrug analog of the antiviral agent penciclovir.  Orally administered, famciclovir in vivo is converted to penciclovir triphosphate, which is active against the Herpes viruses, including herpes simplex 1 and 2 and varicella-zoster.  This agent inhibits the replication of viral DNA by interfering competitively with DNA polymerase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Famciclovir","conceptCode":"C29044","definition":"A diacetyl 6-deoxy prodrug analog of the antiviral agent penciclovir.  Orally administered, famciclovir in vivo is converted to penciclovir triphosphate, which is active against the Herpes viruses, including herpes simplex 1 and 2 and varicella-zoster.  This agent inhibits the replication of viral DNA by interfering competitively with DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B735-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Fluconazole","valueDescription":"Fluconazole","ValueMeaning":{"publicId":"2576944","version":"1","preferredName":"Fluconazole","longName":"2576944","preferredDefinition":"A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluconazole","conceptCode":"C500","definition":"A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F99D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B736-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Foscarnet Sodium","valueDescription":"Foscarnet Sodium","ValueMeaning":{"publicId":"2577879","version":"1","preferredName":"Foscarnet Sodium","longName":"2577879","preferredDefinition":"A synthetic organic analogue of inorganic pyrophosphate with antiviral properties.  Foscarnet (trisodium phosphonoformate) selectively blocks the pyrophosphate binding site of virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases.  Because this agent crosses the blood brain barrier, it may be used in the treatment of viral infections of the CNS.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Foscarnet Sodium","conceptCode":"C1193","definition":"The trisodium salt of a synthetic organic analogue of inorganic pyrophosphate with antiviral activity. Foscarnet selectively blocks the pyrophosphate binding site of herpesvirus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. This agent does not require phosphorylation by thymidine kinase (TK) or other kinases and therefore is active in vitro against herpes simplex virus (HSV) TK deficient mutants and cytomegalovirus (CMV) UL97 mutants. Because foscarnet crosses the blood brain barrier, it may be used in the treatment of viral infections of the CNS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD44-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B737-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Ganciclovir","valueDescription":"Ganciclovir","ValueMeaning":{"publicId":"2575684","version":"1","preferredName":"Ganciclovir","longName":"2575684","preferredDefinition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganciclovir","conceptCode":"C517","definition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B738-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Gentamicin","valueDescription":"Gentamicin","ValueMeaning":{"publicId":"2577881","version":"1","preferredName":"Gentamicin","longName":"2577881","preferredDefinition":"A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1(subA), obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (TRANSLATION (GENETICS)).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gentamicin","conceptCode":"C519","definition":"A broad-spectrum aminoglycoside antibiotic produced by fermentation of Micromonospora purpurea or M. echinospora. Gentamicin is an antibiotic complex consisting of four major (C1, C1a, C2, and C2a) and several minor components. This agent irreversibly binds to the bacterial 30S ribosomal subunit. Specifically, this antibiotic is lodged between 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex, misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B739-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Imipenem","valueDescription":"Imipenem","ValueMeaning":{"publicId":"2578122","version":"1","preferredName":"Imipenem","longName":"2578122","preferredDefinition":"A broad-spectrum, semi-synthetic beta-lactam carbapenem derived from thienamycin, produced by Streptomyces cattleya. Imipenem binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes that are involved in the last stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. This inactivation results in the weakening of the bacterial cell wall and eventually causes cell lysis. Imipenem has the greatest affinity for PBP 1A, 1B, and 2, and its lethal effect is related to binding to PBP 2 and 1B. This antibiotic is active against a wide range of gram-positive and gram-negative organisms and is stable in the presence of beta-lactamases. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imipenem","conceptCode":"C570","definition":"A broad-spectrum, semi-synthetic beta-lactam carbapenem derived from thienamycin, produced by Streptomyces cattleya. Imipenem binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes that are involved in the last stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. This inactivation results in the weakening of the bacterial cell wall and eventually causes cell lysis. Imipenem has the greatest affinity for PBP 1A, 1B, and 2, and its lethal effect is related to binding to PBP 2 and 1B. This antibiotic is active against a wide range of gram-positive and gram-negative organisms and is stable in the presence of beta-lactamases. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE37-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B73A-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Isoniazid","valueDescription":"Isoniazid","ValueMeaning":{"publicId":"2578203","version":"1","preferredName":"Isoniazid","longName":"2578203","preferredDefinition":"A synthetic derivative of nicotinic acid with anti-mycobacterial properties.  Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. Isoniazid also interferes with mycobacterial metabolism of vitamin B6.  Resistance occurs due to decreased bacterial wall penetration. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isoniazid","conceptCode":"C600","definition":"A synthetic derivative of nicotinic acid with anti-mycobacterial properties.  Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. Isoniazid also interferes with mycobacterial metabolism of vitamin B6.  Resistance occurs due to decreased bacterial wall penetration. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B73D-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Itraconazole","valueDescription":"Itraconazole","ValueMeaning":{"publicId":"2578206","version":"1","preferredName":"Itraconazole","longName":"2578206","preferredDefinition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fugal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Itraconazole","conceptCode":"C1138","definition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fungal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B73E-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Ketoconazole","valueDescription":"Ketoconazole","ValueMeaning":{"publicId":"2578210","version":"1","preferredName":"Ketoconazole","longName":"2578210","preferredDefinition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketoconazole","conceptCode":"C605","definition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B73F-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Levofloxacin","valueDescription":"Levofloxacin","ValueMeaning":{"publicId":"2575687","version":"1","preferredName":"Levofloxacin","longName":"2575687","preferredDefinition":"A type of quinolone antibiotic. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levofloxacin","conceptCode":"C1586","definition":"A broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B740-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Lopinavir","valueDescription":"Lopinavir","ValueMeaning":{"publicId":"2575688","version":"1","preferredName":"Lopinavir","longName":"2575688","preferredDefinition":"An anti-HIV protease inhibitor","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lopinavir","conceptCode":"C2095","definition":"A peptidomimetic HIV protease inhibitor that retains activity against HIV protease with the Val 82 mutation. Lopinavir is less affected by binding to serum proteins than the structurally-related drug ritonavir.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B741-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Meropenem","valueDescription":"Meropenem","ValueMeaning":{"publicId":"2578264","version":"1","preferredName":"Meropenem","longName":"2578264","preferredDefinition":"A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative bacteria. It penetrates cell walls and binds to penicillin-binding protein targets. Meropenem acts against aerobes and anaerobes including Klebsiella, E. coli, Enterococcus, Clostridium sp.. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meropenem","conceptCode":"C1160","definition":"A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative bacteria. It penetrates cell walls and binds to penicillin-binding protein targets. Meropenem acts against aerobes and anaerobes including Klebsiella, E. coli, Enterococcus, Clostridium sp.. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B743-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Metronidazole","valueDescription":"Metronidazole","ValueMeaning":{"publicId":"2578274","version":"1","preferredName":"Metronidazole","longName":"2578274","preferredDefinition":"A synthetic nitroimidazole derivative with antiprotozoal and antibacterial. The mechanism of action is not fully elucidated but un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and blocking growth of bacterial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metronidazole","conceptCode":"C651","definition":"A synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. Although its mechanism of action is not fully elucidated, un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is subsequently reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B744-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Miconazole","valueDescription":"Miconazole","ValueMeaning":{"publicId":"2575690","version":"1","preferredName":"Miconazole","longName":"2575690","preferredDefinition":"An antifungal synthetic derivative of imidazole and used in the treatment of candidal skin infections, Miconazole selectively affects the integrity of fungal cell membranes, high in ergosterol content and different in composition from mammalian cells membranes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Miconazole","conceptCode":"C62048","definition":"An antifungal synthetic derivative of imidazole and used in the treatment of candidal skin infections, Miconazole selectively affects the integrity of fungal cell membranes, high in ergosterol content and different in composition from mammalian cells membranes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B745-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Mupirocin","valueDescription":"Mupirocin","ValueMeaning":{"publicId":"2578309","version":"1","preferredName":"Mupirocin","longName":"2578309","preferredDefinition":"A natural crotonic acid derivative extracted from Pseudomonas fluorescens, Mupirocin inhibits bacterial protein synthesis by specific reversible binding to bacterial isoleucyl transfer-RNA synthetase. With excellent activity against gram-positive staphylococci and streptococci, it is primarily used for treatment of primary and secondary skin disorders, nasal infections, and wound healing. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mupirocin","conceptCode":"C29271","definition":"A natural crotonic acid derivative extracted from Pseudomonas fluorescens. Mupirocin inhibits bacterial protein synthesis by specific reversible binding to bacterial isoleucyl tRNA synthase. With excellent activity against gram-positive staphylococci and streptococci, it is primarily used for treatment of primary and secondary skin disorders, nasal infections, and wound healing. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B746-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Nafcillin","valueDescription":"Nafcillin","ValueMeaning":{"publicId":"2575691","version":"1","preferredName":"Nafcillin","longName":"2575691","preferredDefinition":"A semi-synthetic naphthalene and beta-lactam antibiotic with antibacterial activity. Nafcillin inhibits bacterial wall synthesis by a mechanism of action similar to penicillin. Penicillinase-resistant Nafcillin is used to treat infections caused by penicillin-resistant strains of Staphylococci. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nafcillin","conceptCode":"C62053","definition":"A semi-synthetic naphthalene and beta-lactam antibiotic with antibacterial activity. Nafcillin inhibits bacterial wall synthesis by a mechanism of action similar to penicillin. Penicillinase-resistant Nafcillin is used to treat infections caused by penicillin-resistant strains of Staphylococci. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B747-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Nelfinavir","valueDescription":"Nelfinavir","ValueMeaning":{"publicId":"2575692","version":"1","preferredName":"Nelfinavir","longName":"2575692","preferredDefinition":"A synthetic antiviral agent.  Nelfinavir selectively inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions.  In vivo, this agent exhibits broad tissue distribution compared to related agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nelfinavir","conceptCode":"C29285","definition":"A synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease. Nelfinavir has activity against HIV 1 and 2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B748-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Nevirapine","valueDescription":"Nevirapine","ValueMeaning":{"publicId":"2578318","version":"1","preferredName":"Nevirapine","longName":"2578318","preferredDefinition":"A synthetic, non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Nevirapine binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with other antiretroviral drugs, this agent reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nevirapine","conceptCode":"C29277","definition":"A benzodiazepine non-nucleoside reverse transcriptase inhibitor. In combination with other antiretroviral drugs, nevirapine reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEFB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B74A-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2005-09-27","deletedIndicator":"No"},{"value":"Nitrofurantoin","valueDescription":"Nitrofurantoin","ValueMeaning":{"publicId":"2575694","version":"1","preferredName":"Nitrofurantoin","longName":"2575694","preferredDefinition":"A synthetic derivative of imidazolidinedione, Nitrofurantoin inhibits bacterial DNA, RNA, and cell wall protein synthesis. Activated by bacterial flavoproteins to intermediates that inactivate bacterial ribosomal proteins, Nitrofurantoin is used prophylactically as a urinary anti-infective agent against most gram-positive and gram-negative organisms and for long-term suppression of infections. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitrofurantoin","conceptCode":"C29293","definition":"A synthetic derivative of imidazolidinedione, Nitrofurantoin inhibits bacterial DNA, RNA, and cell wall protein synthesis. Activated by bacterial flavoproteins to intermediates that inactivate bacterial ribosomal proteins, Nitrofurantoin is used prophylactically as a urinary anti-infective agent against most gram-positive and gram-negative organisms and for long-term suppression of infections. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B74B-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Nystatin","valueDescription":"Nystatin","ValueMeaning":{"publicId":"2575695","version":"1","preferredName":"Nystatin","longName":"2575695","preferredDefinition":"Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nystatin","conceptCode":"C710","definition":"A polyene macrolide antibiotic, with antifungal activity. Upon administration, nystatin binds to sterols in the fungal plasma membrane, thereby increasing membrane permeability. This leads to leakage of important intracellular components, cell rupture, and eventually fungal cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B74C-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Ofloxacin","valueDescription":"Ofloxacin","ValueMeaning":{"publicId":"2575696","version":"1","preferredName":"Ofloxacin","longName":"2575696","preferredDefinition":"An antibiotic drug used to treat infection. It belongs to the family of drugs called quinolone antibiotics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ofloxacin","conceptCode":"C712","definition":"A fluoroquinolone antibacterial antibiotic. Ofloxacin binds to and inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes involved in DNA replication and repair, resulting in cell death in sensitive bacterial species. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B74D-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Oseltamivir","valueDescription":"Oseltamivir","ValueMeaning":{"publicId":"2575697","version":"1","preferredName":"Oseltamivir","longName":"2575697","preferredDefinition":"A synthetic derivative prodrug of ethyl ester with antiviral activity. Oseltamivir interferes with the final life cycle stage of influenza virus (host cell release of completed viral particles) by blocking neuraminidases on the surface of flu viruses. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oseltamivir","conceptCode":"C62061","definition":"A synthetic derivative prodrug of ethyl ester with antiviral activity. Osetamivir blocks neuraminidases on the surfaces of influenza viruses, interfering with host cell release of complete viral particles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B74E-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Oxacillin Sodium","valueDescription":"Oxacillin Sodium","ValueMeaning":{"publicId":"2575698","version":"1","preferredName":"Oxacillin Sodium","longName":"2575698","preferredDefinition":"The sodium salt form of oxacillin, a semisynthetic penicillinase-resistant and acid-stable penicillin with an antimicrobial activity. Oxacillin binds to penicillin-binding proteins in the bacterial cell wall, thereby blocking the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This leads to inhibition of cell growth and causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxacillin Sodium","conceptCode":"C720","definition":"The sodium salt form of oxacillin, a semisynthetic penicillinase-resistant and acid-stable penicillin with an antimicrobial activity. Oxacillin binds to penicillin-binding proteins in the bacterial cell wall, thereby blocking the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This leads to inhibition of cell growth and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B74F-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Penicillin V","valueDescription":"Penicillin V","ValueMeaning":{"publicId":"2575699","version":"1","preferredName":"Penicillin V","longName":"2575699","preferredDefinition":"A member of the penicillin family exhibiting broad-spectrum antibiotic property. Penicillin V binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, which is a critical component of the bacterial cell wall. This leads to the interruption of cell wall synthesis, consequently leading to bacterial cell growth inhibition and cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penicillin V","conceptCode":"C62064","definition":"A member of the penicillin family exhibiting broad-spectrum antibiotic property. Penicillin V binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, which is a critical component of the bacterial cell wall. This leads to the interruption of cell wall synthesis, consequently leading to bacterial cell growth inhibition and cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B750-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Permethrin","valueDescription":"Permethrin","ValueMeaning":{"publicId":"2575701","version":"1","preferredName":"Permethrin","longName":"2575701","preferredDefinition":"A synthetic pyrethroid and neurotoxin. Permethrin affects the neuronal membrane by blocking the movement of sodium ions from outside to inside the neuronal cell membrane thereby disrupting the sodium channel current that regulates the polarization of the membrane. This leads to delayed repolarization and subsequent paralysis of the nervous system. Permethrin is used to eradicate parasites such as head lice, ticks and scabies from humans and animals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Permethrin","conceptCode":"C29354","definition":"A synthetic pyrethroid and neurotoxin. Permethrin affects the neuronal membrane by blocking the movement of sodium ions from outside to inside the neuronal cell membrane thereby disrupting the sodium channel current that regulates the polarization of the membrane. This leads to delayed repolarization and subsequent paralysis of the nervous system. Permethrin is used to eradicate parasites such as head lice, ticks and scabies from humans and animals.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B752-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Pyrimethamine","valueDescription":"Pyrimethamine","ValueMeaning":{"publicId":"2575705","version":"1","preferredName":"Pyrimethamine","longName":"2575705","preferredDefinition":"A synthetic derivative of ethyl-pyrimidine with potent antimalarial properties.  Pyrimethamine is a competitive inhibitor of dihydrofolate reductase (DHFR).  DHFR is a key enzyme in the redox cycle for production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA and proteins.  This agent is often used in combination with other antimalarials for the treatment of uncomplicated falciparum malaria. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyrimethamine","conceptCode":"C788","definition":"A synthetic derivative of ethyl-pyrimidine with potent antimalarial properties.  Pyrimethamine is a competitive inhibitor of dihydrofolate reductase (DHFR).  DHFR is a key enzyme in the redox cycle for production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA and proteins.  This agent is often used in combination with other antimalarials for the treatment of uncomplicated falciparum malaria. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B756-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Ribavirin","valueDescription":"Ribavirin","ValueMeaning":{"publicId":"2575706","version":"1","preferredName":"Ribavirin","longName":"2575706","preferredDefinition":"A synthetic nucleoside analogue of ribofuranosyl with antiviral activity.  Ribavirin incorporates into viral nucleic acid, inhibits viral ribonucleic acid (RNA) synthesis, induces viral genome mutations, and inhibits normal viral replication.  Ribavirin shows activity against a variety of RNA viruses, especially hepatitis C virus. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ribavirin","conceptCode":"C807","definition":"A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B757-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Rifabutin","valueDescription":"Rifabutin","ValueMeaning":{"publicId":"2575707","version":"1","preferredName":"Rifabutin","longName":"2575707","preferredDefinition":"A semisynthetic ansamycin antibiotic with potent antimycobacterial properties.  Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rifabutin","conceptCode":"C1408","definition":"A semisynthetic ansamycin antibiotic with potent antimycobacterial properties.  Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B758-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Rifampin","valueDescription":"Rifampin","ValueMeaning":{"publicId":"2575708","version":"1","preferredName":"Rifampin","longName":"2575708","preferredDefinition":"A semisynthetic derivative of rifamycin with broad antibacterial activity. Rifampin inhibits DNA-dependent RNA polymerase in susceptible bacteria and is often used in combination with other antibiotics for various infections including tuberculosis. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rifampin","conceptCode":"C811","definition":"A semisynthetic derivative of rifamycin with broad antibacterial activity. Rifampin inhibits DNA-dependent RNA polymerase in susceptible bacteria and is often used in combination with other antibiotics for various infections including tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-20","changeDescription":"Updated definition with current NCIt. mc 11/20/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B759-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Ritonavir","valueDescription":"Ritonavir","ValueMeaning":{"publicId":"2575709","version":"1","preferredName":"Ritonavir","longName":"2575709","preferredDefinition":"A peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ritonavir","conceptCode":"C1609","definition":"A peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4CA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-20","changeDescription":"Updated definition with current NCIt. mc 11/20/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B75A-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Saquinavir","valueDescription":"Fortovase (Saquinavir)","ValueMeaning":{"publicId":"2575710","version":"1","preferredName":"Fortovase (Saquinavir)","longName":"2575710","preferredDefinition":"A synthetic antiviral agent.  Saquinavir, a peptide-like substrate, selectively binds to and inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Saquinavir","conceptCode":"C29444","definition":"A peptidomimetic inhibitor of human immunodeficiency virus (HIV) protease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2012-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B75B-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Sulfacetamide","valueDescription":"Sulfacetamide","ValueMeaning":{"publicId":"2575711","version":"1","preferredName":"Sulfacetamide","longName":"2575711","preferredDefinition":"A synthetic sulfanylacetamide derivative with bacteriostatic activity. Sulfacetamide inhibits bacterial folic acid synthesis by competing with para amino benzoic acid. With a broad spectrum of action, it is used as an anti-infective topical agent to treat skin infections and as an oral agent for urinary tract infections. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sulfacetamide","conceptCode":"C62077","definition":"A synthetic sulfanylacetamide derivative with bacteriostatic activity. Sulfacetamide inhibits bacterial folic acid synthesis by competing with para amino benzoic acid. With a broad spectrum of action, it is used as an anti-infective topical agent to treat skin infections and as an oral agent for urinary tract infections. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4CC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019C7266-B75C-0AAA-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Amphotericin B","valueDescription":"Amphotercin B","ValueMeaning":{"publicId":"2576917","version":"1","preferredName":"Amphotercin B","longName":"2576917","preferredDefinition":"A macrolide antifungal antibiotic produced by Streptomyces nodosus that binds to ergosterol altering cell membrane integrity with subsequent cell death. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amphotericin B","conceptCode":"C238","definition":"A polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, thereby causing depolarization of the membrane and altering cell membrane permeability. This leads to leakage of important intracellular components, cell rupture, and eventually cell death. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F982-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B3433CB-B518-3213-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Combivir","valueDescription":"Lamivudine/Zidovudine","ValueMeaning":{"publicId":"2577823","version":"1","preferredName":"Lamivudine/Zidovudine","longName":"2577823","preferredDefinition":"A combination of two synthetic nucleoside analogues with synergistic antiviral properties.  Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP); zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). These active metabolites inhibit human immunodeficiency virus (HIV) viral reverse transcriptase (RT) by incorporating into viral DNA and terminating viral DNA chain elongation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamivudine/Zidovudine","conceptCode":"C28939","definition":"A combination of two synthetic nucleoside analogues with synergistic antiviral properties.  Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP); zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). These active metabolites inhibit human immunodeficiency virus (HIV) viral reverse transcriptase (RT) by incorporating into viral DNA and terminating viral DNA chain elongation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B3433CB-B552-3213-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Cotrimoxazole","valueDescription":"Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"2577719","version":"1","preferredName":"Trimethoprim-Sulfamethoxazole","longName":"2577719","preferredDefinition":"A combination of two anti-infection drugs, sulfamethoxazole and trimethoprim. It is used to fight bacterial and protozoal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B3433CB-B55F-3213-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Pentamidine Isethionate","valueDescription":"Pentamidine","ValueMeaning":{"publicId":"2743481","version":"1","preferredName":"Pentamidine","longName":"2743481","preferredDefinition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentamidine","conceptCode":"C731","definition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B5A6-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B3433CB-B5BF-3213-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Piperacillin","valueDescription":"Piperacillin Sodium","ValueMeaning":{"publicId":"2743484","version":"1","preferredName":"Piperacillin Sodium","longName":"2743484","preferredDefinition":"Semisynthetic, broad-spectrum, ampicillin-derived ureidopenicillin antibiotic proposed for Pseudomonas infections. It is also used in combination with other antibiotics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piperacillin Sodium","conceptCode":"C749","definition":"The sodium salt of piperacillin, a broad-spectrum semisynthetic, ampicillin-derived ureidopenicillin antibiotic with bactericidal activity. Piperacillin binds to and inactivates penicillin-binding proteins (PBPs), enzymes located on the inner membrane of the bacterial cell wall, resulting in the weakening of the bacterial cell wall and cell lysis. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B5D6-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B3433CB-B5EF-3213-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Linezolid","valueDescription":"Linezolid","ValueMeaning":{"publicId":"2578237","version":"1","preferredName":"Linezolid","longName":"2578237","preferredDefinition":"A synthetic oxazolidinone derivative, Linezolid selectively inhibits an early step in bacterial protein synthesis and affects blood pressure through monoamine oxidase inhibition. It is effective against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus strains, coagulase-negative Staphylococci, vancomycin-resistant Enterococci, and penicillin-resistant Streptococcus pneumoniae strains. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Linezolid","conceptCode":"C29158","definition":"A synthetic oxazolidinone derivative, Linezolid selectively inhibits an early step in bacterial protein synthesis and affects blood pressure through monoamine oxidase inhibition. It is effective against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus strains, coagulase-negative Staphylococci, vancomycin-resistant Enterococci, and penicillin-resistant Streptococcus pneumoniae strains. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEAA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B3433CB-B6E9-3213-E044-0003BA3F9857","beginDate":"2008-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"REEVESD","dateModified":"2008-04-19","deletedIndicator":"No"},{"value":"Aztreonam","valueDescription":"Aztreonam","ValueMeaning":{"publicId":"3134042","version":"1","preferredName":"Aztreonam","longName":"3134042","preferredDefinition":"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum with bactericidal activity.  Azreonam preferentially binds to and inactivates penicillin-binding protein-3 (PBP-3), which is involved in bacterial cell wall synthesis, thereby inhibiting bacterial cell wall integrity and leading to cell lysis and death  This agent differs from other beta-lactam antibiotics because it is resistant to beta-lactamase hydrolysis, and it is usually used to treat infections caused by gram-negative aerobic microorganisms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aztreonam","conceptCode":"C28845","definition":"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum with bactericidal activity. Aztreonam preferentially binds to and inactivates penicillin-binding protein-3 (PBP-3), which is involved in bacterial cell wall synthesis, thereby inhibiting bacterial cell wall integrity and leading to cell lysis and death. This agent differs from other beta-lactam antibiotics because it is resistant to beta-lactamase hydrolysis, and it is usually used to treat infections caused by gram-negative aerobic microorganisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9BB4-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9BCC-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Cefepime HCL","valueDescription":"Cefepime","ValueMeaning":{"publicId":"2577796","version":"1","preferredName":"Cefepime","longName":"2577796","preferredDefinition":"A semi-synthetic, broad spectrum, fourth generation cephalosporin antibiotic which inhibits bacterial cell wall biosynthesis by interfering with the final transpeptidation step of peptidoglycan synthesis which ultimately causes the bacterial to lyse. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefepime Hydrochloride","conceptCode":"C1041","definition":"The hydrochloride salt of a semi-synthetic, beta-lactamase-resistant, fourth-generation cephalosporin antibiotic derived from an Acremonium fungal species with broad-spectrum bactericidal activity. Administered parenterally, cefepime inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, resulting in a reduction of bacterial cell wall stability and cell lysis. This agent is more active against a variety of Gram-positive pathogens compared to third-generation cephalosporins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9BE1-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Ethambutol HCL","valueDescription":"Ethambutol","ValueMeaning":{"publicId":"3134044","version":"1","preferredName":"Ethambutol","longName":"3134044","preferredDefinition":"An antibiotic with bacteriostatic, antimicrobial and antitubercular properties. Ethambutol interferes with the biosynthesis of arabinogalactan, a major polysaccharide of the mycobacterial cell wall. It inhibits the polymerization of cell wall arabinan of arabinogalactan and lipoarabinomannan by blocking arabinosyl transferases and induces the accumulation of D-arabinofuranosyl-P-decaprenol, an intermediate in arabinan biosynthesis. This results in halting bacterial growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethambutol","conceptCode":"C61755","definition":"An antibiotic with bacteriostatic, antimicrobial and antitubercular properties. Ethambutol interferes with the biosynthesis of arabinogalactan, a major polysaccharide of the mycobacterial cell wall. It inhibits the polymerization of cell wall arabinan of arabinogalactan and lipoarabinomannan by blocking arabinosyl transferases and induces the accumulation of D-arabinofuranosyl-P-decaprenol, an intermediate in arabinan biosynthesis. This results in halting bacterial growth.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9BEE-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9C07-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Doxycycline Chloride","valueDescription":"Doxycycline Monohydrate","ValueMeaning":{"publicId":"2577865","version":"1","preferredName":"Doxycycline Monohydrate","longName":"2577865","preferredDefinition":"A synthetic tetracycline derivative exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline","conceptCode":"C457","definition":"A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD36-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"REEVESD","dateModified":"2010-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B8ED6E9-EA53-3596-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"REEVESD","dateModified":"2008-04-23","deletedIndicator":"No"},{"value":"Indinavir","valueDescription":"Indinavir Sulfate","ValueMeaning":{"publicId":"2578193","version":"1","preferredName":"Indinavir Sulfate","longName":"2578193","preferredDefinition":"A synthetic antiviral agent. Indinavir selectively inhibits human immunodeficiency virus (HIV) protease, an essential enzyme for replication and maturation of viral particles. HIV protease inhibition prevents the normal cleavage of gag-pol viral polyproteins, resulting in the release of immature, noninfectious virions and protection of healthy host cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indinavir Sulfate","conceptCode":"C1662","definition":"A synthetic antiviral agent. Indinavir selectively binds to the active site of human immunodeficiency virus (HIV) protease and inhibits its activity, preventing the protease-mediated cleavage of gag-pol viral polyproteins; as a result immature, noninfectious virions are produced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B8ED6E9-EA5F-3596-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"REEVESD","dateModified":"2008-04-23","deletedIndicator":"No"},{"value":"Ivermectin","valueDescription":"Ivermectin","ValueMeaning":{"publicId":"2578208","version":"1","preferredName":"Ivermectin","longName":"2578208","preferredDefinition":"A macrocyclic lactone derived from Streptomyces avermitilis with antiparasitic activity. Ivermectin exerts its anthelmintic effect via activating glutamate-gated chloride channels expressed on nematode neurons and pharyngeal muscle cells. Distinct from the channel opening induced by endogenous glutamate transmitter, ivermectin-activated channels open very slowly but essentially irreversibly. As a result, neurons or muscle cells remain at either hyperpolarisation or depolarization state, thereby resulting in paralysis and death of the parasites. Ivermectin does not readily pass the mammal blood-brain barrier to the central nervous system where glutamate-gated chloride channels locate, hence the hosts are relatively resistant to the effects of this agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ivermectin","conceptCode":"C61796","definition":"An orally bioavailable macrocyclic lactone derived from Streptomyces avermitilis, with antiparasitic and potential anti-viral activities. Upon administration, ivermectin exerts its anthelmintic effect through binding and activating glutamate-gated chloride channels (GluCls) expressed on nematode neurons and pharyngeal muscle cells. This causes increased permeability of chloride ions, causing a state of hyperpolarization and results in the paralysis and death of the parasite. Ivermectin may exerts its antiviral effect, including its potential activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), by binding to the importin (IMP) alpha/beta1 heterodimer, which is responsible for the nuclear import of viral proteins such as the integrase (IN) protein. This inhibits nuclear import of host and viral proteins and may inhibit viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"REEVESD","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B8ED6E9-EA71-3596-E044-0003BA3F9857","beginDate":"2008-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"REEVESD","dateModified":"2008-04-23","deletedIndicator":"No"},{"value":"Lopinavir/Ritonavir","valueDescription":"Lopinavir/Ritonavir","ValueMeaning":{"publicId":"2578201","version":"1","preferredName":"Lopinavir/Ritonavir","longName":"2578201","preferredDefinition":"A combination anti-HIV protease inhibitor from Abbott Laboratories.  Brand name is Kaletra.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lopinavir/Ritonavir","conceptCode":"C2096","definition":"A fixed combination of two protease inhibitors, lopinavir and ritonavir, used to treat human immunodeficiency virus (HIV) infection. The ritonavir in the combination drug increases the concentration and biological half-life of lopinavir but is not present in sufficient concentration to act as a protease inhibitor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE86-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B8ED6E9-EA86-3596-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"REEVESD","dateModified":"2008-04-23","deletedIndicator":"No"},{"value":"Neosporin","valueDescription":"Neosporin Cream","ValueMeaning":{"publicId":"2578316","version":"1","preferredName":"Neosporin Cream","longName":"2578316v1.00","preferredDefinition":"A combination preparation containing the aminoglycoside antibiotic neomycin sulfate, the polypeptide antibiotic polymyxin B sulfate and bacitracin zinc, with topical antibacterial activity. Polymyxin B sulfate, a polypeptide produced by Bacillus polymyxa, binds to negatively charged phospholipids in the cell membrane, thereby altering the permeability of the bacterial cytoplasmic membrane. Neomycin sulfate, an aminoglycoside antibiotic, irreversibly binds to the bacterial 30S ribosomal subunit, thereby preventing mRNA from binding to the 30S subunit, causes misreading and inhibits protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neomycin/Polymyxin B/Bacitracin Zinc","conceptCode":"C29286","definition":"A combination preparation containing the aminoglycoside antibiotic neomycin sulfate, the polypeptide antibiotic polymyxin B sulfate and bacitracin zinc, with topical antibacterial activity. Polymyxin B sulfate, a polypeptide produced by Bacillus polymyxa, binds to negatively charged phospholipids in the cell membrane, thereby altering the permeability of the bacterial cytoplasmic membrane. Neomycin sulfate, an aminoglycoside antibiotic, irreversibly binds to the bacterial 30S ribosomal subunit, thereby preventing mRNA from binding to the 30S subunit, causes misreading and inhibits protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B8ED6E9-EA9B-3596-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"REEVESD","dateModified":"2008-04-23","deletedIndicator":"No"},{"value":"Gatifloxacin","valueDescription":"Gatifloxacin","ValueMeaning":{"publicId":"3134045","version":"1","preferredName":"Gatifloxacin","longName":"3134045","preferredDefinition":"A synthetic 8-methoxyfluoroquinolone with antibacterial activity against a wide range of gram-negative and gram-positive microorganisms. Gatifloxacin exerts its effect through inhibition of DNA gyrase, an enzyme involved in DNA replication, transcription and repair, and inhibition of topoisomerase IV, an enzyme involved in partitioning of chromosomal DNA during bacterial cell division.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gatifloxacin","conceptCode":"C29070","definition":"A synthetic 8-methoxyfluoroquinolone with antibacterial activity against a wide range of gram-negative and gram-positive microorganisms. Gatifloxacin exerts its effect through inhibition of DNA gyrase, an enzyme involved in DNA replication, transcription and repair, and inhibition of topoisomerase IV, an enzyme involved in partitioning of chromosomal DNA during bacterial cell division.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9C11-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9C29-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Piperacillin Sodium/Tazobactam Sodium","valueDescription":"Piperacillin-Tazobactam","ValueMeaning":{"publicId":"2744249","version":"1","preferredName":"Piperacillin-Tazobactam","longName":"2744249","preferredDefinition":"A combination formulation of the antibiotic piperacillin and the beta-lactamase inhibitor tazobactam with antibacterial activity. Piperacillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. Tazobactam, a penicillanic acid sulfone derivative, irreversibly binds to and inhibits bacterial beta-lactamase at or near its active site, thereby preventing the destruction of the beta-lactamase susceptible piperacillin by this bacterial enzyme.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piperacillin-Tazobactam","conceptCode":"C1530","definition":"A combination formulation of the antibiotic piperacillin and the beta-lactamase inhibitor tazobactam with antibacterial activity. Piperacillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. Tazobactam, a penicillanic acid sulfone derivative, irreversibly binds to and inhibits bacterial beta-lactamase at or near its active site, thereby preventing the destruction of the beta-lactamase susceptible piperacillin by this bacterial enzyme.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8ED6E9-EAB6-3596-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B8ED6E9-EACF-3596-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"REEVESD","dateModified":"2008-04-23","deletedIndicator":"No"},{"value":"Sulfamethoxazole/Trimethoprim","valueDescription":"Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"2577719","version":"1","preferredName":"Trimethoprim-Sulfamethoxazole","longName":"2577719","preferredDefinition":"A combination of two anti-infection drugs, sulfamethoxazole and trimethoprim. It is used to fight bacterial and protozoal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B8ED6E9-EAE4-3596-E044-0003BA3F9857","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"REEVESD","dateModified":"2008-04-23","deletedIndicator":"No"},{"value":"Terbinafine HCL","valueDescription":"Terbinafine","ValueMeaning":{"publicId":"2743495","version":"1","preferredName":"Terbinafine","longName":"2743495","preferredDefinition":"A synthetic allylamine derivative with antifungal activity. Terbinafine exerts its effect through inhibition of squalene epoxidase, thereby blocking the biosynthesis of ergosterol, an important component of fungal cell membranes. As a result, this agent disrupts fungal cell membrane synthesis and inhibits fungal growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Terbinafine","conceptCode":"C48019","definition":"A synthetic allylamine derivative with antifungal activity. Terbinafine exerts its effect through inhibition of squalene epoxidase, thereby blocking the biosynthesis of ergosterol, an important component of fungal cell membranes. As a result, this agent disrupts fungal cell membrane synthesis and inhibits fungal growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B63E-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9C3E-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Tetracycline HCL","valueDescription":"Tetracycline","ValueMeaning":{"publicId":"2743497","version":"1","preferredName":"Tetracycline","longName":"2743497","preferredDefinition":"A broad-spectrum naphthacene antibiotic produced semisynthetically from chlortetracycline, an antibiotic isolated from the bacterium Streptomyces aureofaciens. In bacteria, tetracycline binds to the 30S ribosomal subunit, interferes with the binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tetracycline","conceptCode":"C865","definition":"A broad-spectrum naphthacene antibiotic produced semisynthetically from chlortetracycline, an antibiotic isolated from the bacterium Streptomyces aureofaciens. In bacteria, tetracycline binds to the 30S ribosomal subunit, interferes with the binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B668-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9C52-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Valacyclovir HCL","valueDescription":"Valacyclovir","ValueMeaning":{"publicId":"2743501","version":"1","preferredName":"Valacyclovir","longName":"2743501","preferredDefinition":"The hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Orally administered, valacyclovir is rapidly converted to acyclovir which inhibits viral DNA replication after further conversion to the nucleotide analog acyclovir triphosphate by viral thymidine kinase, cellular guanyl cyclase, and a number of other cellular enzymes. Acyclovir triphosphate competitively inhibits viral DNA polymerase; incorporates into and terminates the growing viral DNA chain; and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against herpes simplex virus (HSV) compared with varicella-zoster virus (VZV) is due to its more efficient phosphorylation by HSV thymidine kinase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valacyclovir","conceptCode":"C28235","definition":"The hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Orally administered, valacyclovir is rapidly converted to acyclovir which inhibits viral DNA replication after further conversion to the nucleotide analog acyclovir triphosphate by viral thymidine kinase, cellular guanyl cyclase, and a number of other cellular enzymes. Acyclovir triphosphate competitively inhibits viral DNA polymerase; incorporates into and terminates the growing viral DNA chain; and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against herpes simplex virus (HSV) compared with varicella-zoster virus (VZV) is due to its more efficient phosphorylation by HSV thymidine kinase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B6A5-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"COOPERM","dateModified":"2018-03-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9C66-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Terconazole","valueDescription":"Terconazole","ValueMeaning":{"publicId":"3134048","version":"1","preferredName":"Terconazole","longName":"3134048","preferredDefinition":"A synthetic triazole derivative structurally related to fluconazole, antifungal Terconazole seems to disrupt cell wall synthesis by inhibiting biosynthesis of ergosterol or other sterols, damaging the fungal cell membrane, altering its permeability, and promoting loss of essential intracellular elements.  Terconazole is active against Candida sp.. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Terconazole","conceptCode":"C29493","definition":"A synthetic triazole derivative structurally related to fluconazole, antifungal Terconazole seems to disrupt cell wall synthesis by inhibiting biosynthesis of ergosterol or other sterols, damaging the fungal cell membrane, altering its permeability, and promoting loss of essential intracellular elements.  Terconazole is active against Candida sp.. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0FC943-270F-2DAE-E040-BB89AD435236","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0FC943-2728-2DAE-E040-BB89AD435236","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Anidulafungin","valueDescription":"Anidulafungin","ValueMeaning":{"publicId":"2762697","version":"1","preferredName":"Anidulafungin","longName":"2762697","preferredDefinition":"A cyclic lipopeptide echinocandin derivative with antifungal activity.  Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anidulafungin","conceptCode":"C38716","definition":"A cyclic lipopeptide echinocandin derivative with antifungal activity.  Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5111047F-8F59-4420-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5111047F-8F72-4420-E044-0003BA3F9857","beginDate":"2008-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-02","modifiedBy":"REEVESD","dateModified":"2008-07-02","deletedIndicator":"No"},{"value":"Micafungin Sodium","valueDescription":"Micafungin","ValueMeaning":{"publicId":"2794943","version":"1","preferredName":"Micafungin","longName":"2794943","preferredDefinition":"A semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Inhibition of this enzyme weakens of the cell wall, thereby leading to osmotic lysis and eventually, fungal cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Micafungin","conceptCode":"C1850","definition":"A semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Inhibition of this enzyme weakens of the cell wall, thereby leading to osmotic lysis and eventually, fungal cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A00A568-3058-15CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"5.5.17  Updated concept definition to synch with current NCIt. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"817312F9-5A05-37DB-E040-BB89AD437AE8","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-10","modifiedBy":"ONEDATA","dateModified":"2010-03-10","deletedIndicator":"No"},{"value":"Daptomycin","valueDescription":"Daptomycin","ValueMeaning":{"publicId":"2939026","version":"1","preferredName":"Daptomycin","longName":"2939026","preferredDefinition":"A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum antibiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daptomycin","conceptCode":"C47470","definition":"A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum antibiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4A6A-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8496CD40-BEE3-38E5-E040-BB89AD431EE9","beginDate":"2010-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-19","modifiedBy":"ONEDATA","dateModified":"2010-04-19","deletedIndicator":"No"},{"value":"Moxifloxacin HCL","valueDescription":"Moxifloxacin","ValueMeaning":{"publicId":"2743466","version":"1","preferredName":"Moxifloxacin","longName":"2743466","preferredDefinition":"A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Moxifloxacin","conceptCode":"C62052","definition":"A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B4DB-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0F9C5F-9831-93F6-E040-BB89AD43104E","beginDate":"2008-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Doxycycline Monohydrate","valueDescription":"Doxycycline Monohydrate","ValueMeaning":{"publicId":"2577865","version":"1","preferredName":"Doxycycline Monohydrate","longName":"2577865","preferredDefinition":"A synthetic tetracycline derivative exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline","conceptCode":"C457","definition":"A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD36-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"REEVESD","dateModified":"2010-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F2112BE-1DBA-4AC0-E040-BB89AD4348D8","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-31","modifiedBy":"ONEDATA","dateModified":"2010-08-31","deletedIndicator":"No"},{"value":"ddC","valueDescription":"Zalcitabine","ValueMeaning":{"publicId":"2576782","version":"1","preferredName":"Zalcitabine","longName":"2576782","preferredDefinition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zalcitabine","conceptCode":"C430","definition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8FB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9A6B-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"ddI","valueDescription":"Didanosine","ValueMeaning":{"publicId":"2576104","version":"1","preferredName":"Didanosine","longName":"2576104","preferredDefinition":"A synthetic nucleoside analogue of deoxyadenosine in which the 3' hydroxyl on the ribose moiety is replaced by a hydrogen atom. In vivo, didanosine is converted to the active triphosphate form, which is incorporated into DNA. The absence of the 3' hydroxyl inhibits DNA elongation because phosphodiester bonds cannot be made with the substituted hydrogen. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Didanosine","conceptCode":"C431","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F655-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9A76-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Demeclocycline HCL","valueDescription":"Demeclocycline","ValueMeaning":{"publicId":"2744246","version":"1","preferredName":"Demeclocycline","longName":"2744246","preferredDefinition":"A semi-synthetic, broad-spectrum naphthacene antibiotic produced by the bacterium Streptomyces aureofaciens. Demeclocycline binds to bacterial 30S ribosomal subunit and prevents binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. Demeclocycline also inhibits the effect of vasopressin on the renal tubules, thereby causing diuresis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Demeclocycline","conceptCode":"C47980","definition":"A semi-synthetic, broad-spectrum naphthacene antibiotic produced by the bacterium Streptomyces aureofaciens. Demeclocycline binds to bacterial 30S ribosomal subunit and prevents binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. Demeclocycline also inhibits the effect of vasopressin on the renal tubules, thereby causing diuresis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8ED6E9-EA2E-3596-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9A94-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Dicloxacillin","valueDescription":"Dicloxacillin","ValueMeaning":{"publicId":"3134041","version":"1","preferredName":"Dicloxacillin","longName":"3134041","preferredDefinition":"A broad-spectrum, semi-synthetic, beta-lactam, penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Dicloxacillin binds to penicillin binding proteins (PBP) located on the inner membrane of the bacterial cell wall. It also inhibits the cross-linkage of peptidoglycan, a critical component of bacterial cell walls. This leads to the inhibition of bacterial cell wall synthesis and eventually causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dicloxacillin","conceptCode":"C28986","definition":"A broad-spectrum, semi-synthetic, beta-lactam, penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Dicloxacillin binds to penicillin binding proteins (PBP) located on the inner membrane of the bacterial cell wall.  It also inhibits the cross-linkage of peptidoglycan, a critical component of bacterial cell walls. This leads to the inhibition of bacterial cell wall synthesis and eventually causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F0E6EAA-9A9E-CEBC-E040-BB89AD435B8F","latestVersionIndicator":"Yes","beginDate":"2010-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0E6EAA-9AB6-CEBC-E040-BB89AD435B8F","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-30","modifiedBy":"ONEDATA","dateModified":"2010-08-30","deletedIndicator":"No"},{"value":"Phenoxymethylpenicillin","valueDescription":"Penicillin V","ValueMeaning":{"publicId":"2575699","version":"1","preferredName":"Penicillin V","longName":"2575699","preferredDefinition":"A member of the penicillin family exhibiting broad-spectrum antibiotic property. Penicillin V binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, which is a critical component of the bacterial cell wall. This leads to the interruption of cell wall synthesis, consequently leading to bacterial cell growth inhibition and cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penicillin V","conceptCode":"C62064","definition":"A member of the penicillin family exhibiting broad-spectrum antibiotic property. Penicillin V binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, which is a critical component of the bacterial cell wall. This leads to the interruption of cell wall synthesis, consequently leading to bacterial cell growth inhibition and cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"965EBE14-FA59-BB4E-E040-BB89AD434D9D","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"ONEDATA","dateModified":"2010-12-01","deletedIndicator":"No"},{"value":"Imipenem/Cilastatin","valueDescription":"Imipenem-Cilastatin Sodium","ValueMeaning":{"publicId":"2578191","version":"1","preferredName":"Imipenem-Cilastatin Sodium","longName":"2578191","preferredDefinition":"A combination antibiotic containing Imipenem, a broad spectrum beta-lactam antibiotic, and Cilastatin Sodium, an agent that reduces metabolism of Imipenem by inhibiting dehydropeptidase, used in treating severe infections caused by multiresistant organisms.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imipenem-Cilastatin Sodium","conceptCode":"C2338","definition":"A parenteral antibiotic preparation containing imipenem and cilastatin sodium with bactericidal activity. Imipenem, a broad spectrum beta-lactam antibiotic, binds to penicillin-binding proteins (PBP) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. Cilastatin sodium is added to reduce breakdown of imipenem by kidney dehydropeptidase.  This agent is effective against both gram positive and negative bacteria and is often used in treating severe infections caused by multiresistant organisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"965EBE14-FA63-BB4E-E040-BB89AD434D9D","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"ONEDATA","dateModified":"2010-12-01","deletedIndicator":"No"},{"value":"Didanosine EC","valueDescription":"Extended Release Dosage Form Didanosine","ValueMeaning":{"publicId":"3163428","version":"1","preferredName":"Extended Release Dosage Form Didanosine","longName":"3163428","preferredDefinition":"A solid, semi-solid, solution or suspension designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.: A synthetic nucleoside analogue of deoxyadenosine in which the 3' hydroxyl on the ribose moiety is replaced by a hydrogen atom. In vivo, didanosine is converted to the active triphosphate form, which is incorporated into DNA. The absence of the 3' hydroxyl inhibits DNA elongation because phosphodiester bonds cannot be made with the substituted hydrogen. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extended Release Dosage Form","conceptCode":"C42713","definition":"A solid, semi-solid, solution or suspension designed to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Didanosine","conceptCode":"C431","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"965EBE14-FA71-BB4E-E040-BB89AD434D9D","latestVersionIndicator":"Yes","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"965EBE14-FA8A-BB4E-E040-BB89AD434D9D","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"ONEDATA","dateModified":"2010-12-01","deletedIndicator":"No"},{"value":"Colistimethate","valueDescription":"Colistimethate (Colistin)","ValueMeaning":{"publicId":"3163429","version":"1","preferredName":"Colistimethate (Colistin)","longName":"3163429","preferredDefinition":"A broad-spectrum polymyxin antibiotic against most aerobic Gram-negative bacteria (except Proteus).  Colistimethate is a mixture of methanesulfonate derivatives of cyclic polypeptides colistin A and B from Bacillus colistinus or B. polymyxa.  Colistin functions as a surfactant which penetrates into and disrupts the bacterial cell membrane, thereby resulting in bactericidal effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colistimethate","conceptCode":"C72729","definition":"A broad-spectrum polymyxin antibiotic against most aerobic Gram-negative bacteria except Proteus bacteria. Colistimethate is a mixture of methanesulfonate derivatives of cyclic polypeptides colistin A and B from Bacillus colistinus or B. polymyxa. Colistin functions as a surfactant which penetrates into and disrupts the bacterial cell membrane, thereby resulting in bactericidal effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"965EBE14-FA94-BB4E-E040-BB89AD434D9D","latestVersionIndicator":"Yes","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"965EBE14-FAAC-BB4E-E040-BB89AD434D9D","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"ONEDATA","dateModified":"2010-12-01","deletedIndicator":"No"},{"value":"ddi DS","valueDescription":"Double Pharmaceutical Strength Didanosine","ValueMeaning":{"publicId":"3163431","version":"1","preferredName":"Double Pharmaceutical Strength Didanosine","longName":"3163431","preferredDefinition":"A twofold increase.: The content of an active ingredient expressed quantitatively per dosage unit, per unit of volume, or per unit of weight, according to the pharmaceutical dose form.: A synthetic nucleoside analogue of deoxyadenosine in which the 3' hydroxyl on the ribose moiety is replaced by a hydrogen atom. In vivo, didanosine is converted to the active triphosphate form, which is incorporated into DNA. The absence of the 3' hydroxyl inhibits DNA elongation because phosphodiester bonds cannot be made with the substituted hydrogen. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Double","conceptCode":"C54574","definition":"A twofold increase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pharmaceutical Strength","conceptCode":"C53294","definition":"The content of an active ingredient expressed quantitatively per dosage unit, per unit of volume, or per unit of weight, according to the pharmaceutical dose form.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Didanosine","conceptCode":"C431","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"965EBE14-FAF2-BB4E-E040-BB89AD434D9D","latestVersionIndicator":"Yes","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"965EBE14-FB0B-BB4E-E040-BB89AD434D9D","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"ONEDATA","dateModified":"2010-12-01","deletedIndicator":"No"},{"value":"Undecyclenic Acid","valueDescription":"Undecylenic Acid","ValueMeaning":{"publicId":"3163439","version":"1","preferredName":"Undecylenic Acid","longName":"3163439","preferredDefinition":"A natural or synthetic fungistatic fatty acid, antifungal Undecylenic Acid is used topically as a zinc salt in various creams against fungal infections, eczemas, ringworm, and other cutaneous conditions. The zinc provides an astringent action, reducing rawness and irritation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undecylenic Acid","conceptCode":"C29530","definition":"A natural or synthetic fungistatic fatty acid, antifungal Undecylenic Acid is used topically as a zinc salt in various creams against fungal infections, eczemas, ringworm, and other cutaneous conditions. The zinc provides an astringent action, reducing rawness and irritation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"965F08E8-5861-644B-E040-BB89AD4369A3","latestVersionIndicator":"Yes","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"965F08E8-587A-644B-E040-BB89AD4369A3","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"ONEDATA","dateModified":"2010-12-01","deletedIndicator":"No"},{"value":"Sulfamethoxazole/Trimethoprim (Bactrim) DS","valueDescription":"Double Pharmaceutical Strength Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"3163440","version":"1","preferredName":"Double Pharmaceutical Strength Trimethoprim-Sulfamethoxazole","longName":"3163440","preferredDefinition":"A twofold increase.: The content of an active ingredient expressed quantitatively per dosage unit, per unit of volume, or per unit of weight, according to the pharmaceutical dose form.: A combination of two anti-infection drugs, sulfamethoxazole and trimethoprim. It is used to fight bacterial and protozoal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Double","conceptCode":"C54574","definition":"A twofold increase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pharmaceutical Strength","conceptCode":"C53294","definition":"The content of an active ingredient expressed quantitatively per dosage unit, per unit of volume, or per unit of weight, according to the pharmaceutical dose form.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"965F08E8-589F-644B-E040-BB89AD4369A3","latestVersionIndicator":"Yes","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"ONEDATA","dateModified":"2010-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"965F08E8-58B8-644B-E040-BB89AD4369A3","beginDate":"2010-12-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-01","modifiedBy":"ONEDATA","dateModified":"2010-12-01","deletedIndicator":"No"},{"value":"Paecilomyces variotii","valueDescription":"Paecilomyces variotii","ValueMeaning":{"publicId":"3297319","version":"1","preferredName":"Paecilomyces variotii","longName":"3297319v1.00","preferredDefinition":"A species of fungi in the family Trichocomacae characterized by broadly ellipsoidal to lemon-shaped conidia, loosely branched conidiophores and phialides with pointed tips. B. spectabilis is strongly heat-resistant and is a common contaminant of heat-treated foods and juices.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Byssochlamys spectabilis","conceptCode":"C127694","definition":"A species of fungi in the family Trichocomacae characterized by broadly ellipsoidal to lemon-shaped conidia, loosely branched conidiophores and phialides with pointed tips. B. spectabilis is strongly heat-resistant and is a common contaminant of heat-treated foods and juices.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFD20E49-7454-0102-E040-BB89AD4354C5","latestVersionIndicator":"Yes","beginDate":"2011-10-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-21","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AFD20E49-746D-0102-E040-BB89AD4354C5","beginDate":"2011-10-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-21","modifiedBy":"ONEDATA","dateModified":"2011-10-21","deletedIndicator":"No"},{"value":"Ertapenem","valueDescription":"Ertapenem","ValueMeaning":{"publicId":"3243440","version":"1","preferredName":"Ertapenem","longName":"3243440","preferredDefinition":"A 1-beta-methyl carbapenem and broad-spectrum beta-lactam antibiotic with bactericidal property. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and subsequent lysis of the cell wall leading to cell death of Gram-positive and Gram-negative aerobic and anaerobic pathogens. This agent is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ertapenem","conceptCode":"C61752","definition":"A 1-beta-methyl carbapenem and broad-spectrum beta-lactam antibiotic with bactericidal property. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and subsequent lysis of the cell wall leading to cell death of Gram-positive and Gram-negative aerobic and anaerobic pathogens. This agent is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-322F-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A55A32E7-3248-D7C0-E040-BB89AD437508","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"ONEDATA","dateModified":"2011-06-10","deletedIndicator":"No"},{"value":"Tigecycline","valueDescription":"Tigecycline","ValueMeaning":{"publicId":"2939028","version":"1","preferredName":"Tigecycline","longName":"2939028v1.00","preferredDefinition":"A broad-spectrum glycylcycline antibiotic derived from tetracycline. Tigecycline binds to the 30S ribosomal subunit, thereby interfering with the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This prevents the incorporation of amino acid residues into the elongating peptide chain, inhibiting protein synthesis and eventually bacterial cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tigecycline","conceptCode":"C72865","definition":"A broad-spectrum glycylcycline antibiotic derived from tetracycline. Tigecycline binds to the 30S ribosomal subunit, thereby interfering with the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This prevents the incorporation of amino acid residues into the elongating peptide chain, inhibiting protein synthesis and eventually bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4A90-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-3418-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Streptomycin","valueDescription":"Streptomycin","ValueMeaning":{"publicId":"3874323","version":"1","preferredName":"Streptomycin","longName":"3874323","preferredDefinition":"An aminoglycoside antibiotic derived from Streptomyces griseus with antibacterial activity. Streptomycin irreversibly binds to the 16S rRNA and S12 protein within the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, streptomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Streptomycin","conceptCode":"C61952","definition":"An aminoglycoside antibiotic derived from Streptomyces griseus with antibacterial activity. Streptomycin irreversibly binds to the 16S rRNA and S12 protein within the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, streptomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-3425-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-343E-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Quinupristin/Dalfopristin","valueDescription":"Quinupristin/Dalfopristin","ValueMeaning":{"publicId":"3874324","version":"1","preferredName":"Quinupristin/Dalfopristin","longName":"3874324v1.00","preferredDefinition":"A semi-synthetic derivative of pristinamycin, a natural occurring type B streptogramin. Quinupristin binds to the bacterial 50S ribosomal subunit, thereby inhibiting peptide chain elongation, and causing early termination of normal bacterial protein synthesis. Quinupristin is primarily effective against gram-positive cocci._A semi-synthetic derivative of streptogramin A produced by streptomycetes. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome by binding to the 70S subunit, and also alters the configuration of the ribosome to make it more susceptible for streptogramin B binding. Dalfopristin is used in combination with quinopristin, a streptogramin B derivative. This combination is active against most gram-positive organisms, including Enterococcus faecium, and is also active against some gram-negative organisms and mycoplasma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quinupristin","conceptCode":"C47701","definition":"A semi-synthetic derivative of pristinamycin, a natural occurring type B streptogramin. Quinupristin binds to the bacterial 50S ribosomal subunit, thereby inhibiting peptide chain elongation, and causing early termination of normal bacterial protein synthesis. Quinupristin is primarily effective against gram-positive cocci.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dalfopristin","conceptCode":"C47468","definition":"A semi-synthetic derivative of streptogramin A produced by streptomycetes. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome by binding to the 70S subunit, and also alters the configuration of the ribosome to make it more susceptible for streptogramin B binding. Dalfopristin is used in combination with quinopristin, a streptogramin B derivative. This combination is active against most gram-positive organisms, including Enterococcus faecium, and is also active against some gram-negative organisms and mycoplasma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-3448-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-3461-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Posaconazole","valueDescription":"Posaconazole","ValueMeaning":{"publicId":"2794973","version":"1","preferredName":"Posaconazole","longName":"2794973","preferredDefinition":"A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Posaconazole","conceptCode":"C61500","definition":"A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F070-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-346B-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Polymyxin","valueDescription":"Polymyxin Antibiotic","ValueMeaning":{"publicId":"3335083","version":"1","preferredName":"Polymyxin Antibiotic","longName":"3335083","preferredDefinition":"Any of the polymyxin antibiotics, cyclic peptides with long hydrophobic ends, obtained from Bacillus polymyxa strains. Polymyxin antibiotics exert their antimicrobial effect through their cationic detergent actions on cell membranes. Specifically, they bind to the negatively charged site in the lipopolysaccharide (LPS) layer of the bacterial cell membrane via electrostatic affinity with the positively charged amino groups in the cyclic peptide portion of the polymyxin antibiotic. Subsequently, the fatty acid portion of the polymyxin antibiotic dissolves in the hydrophobic region of the bacterial cell membrane. This results in an alteration in cell membrane structure, an increase in permeability for water and other molecules and disruption of cell wall integrity. This leads to bacterial cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymyxin Antibiotic","conceptCode":"C78160","definition":"Any of the polymyxin antibiotics, cyclic peptides with long hydrophobic ends, obtained from Bacillus polymyxa strains. Polymyxin antibiotics exert their antimicrobial effect through their cationic detergent actions on cell membranes. Specifically, they bind to the negatively charged site in the lipopolysaccharide (LPS) layer of the bacterial cell membrane via electrostatic affinity with the positively charged amino groups in the cyclic peptide portion of the polymyxin antibiotic. Subsequently, the fatty acid portion of the polymyxin antibiotic dissolves in the hydrophobic region of the bacterial cell membrane. This results in an alteration in cell membrane structure, an increase in permeability for water and other molecules and disruption of cell wall integrity. This leads to bacterial cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EC0F-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-347F-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Norfloxacin","valueDescription":"Norfloxacin","ValueMeaning":{"publicId":"3874326","version":"1","preferredName":"Norfloxacin","longName":"3874326","preferredDefinition":"A synthetic, broad-spectrum fluoroquinolone with antibacterial activity. Norfloxacin inhibits activity of DNA gyrase, thereby blocking bacterial DNA replication. Norfloxacin concentrates in the renal tubules and bladder and is bactericidal against a wide range of aerobic gram-positive and gram-negative organisms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Norfloxacin","conceptCode":"C47638","definition":"A synthetic, broad-spectrum fluoroquinolone with antibacterial activity. Norfloxacin inhibits activity of DNA gyrase, thereby blocking bacterial DNA replication. Norfloxacin concentrates in the renal tubules and bladder and is bactericidal against a wide range of aerobic gram-positive and gram-negative organisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-348C-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-34A5-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Neomycin","valueDescription":"Neomycin","ValueMeaning":{"publicId":"3874328","version":"1","preferredName":"Neomycin","longName":"3874328","preferredDefinition":"A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neomycin","conceptCode":"C683","definition":"A broad spectrum aminoglycoside antibiotic derived from Streptomyces fradiae with antibacterial activity. Neomycin is an antibiotic complex consisting of 3 components: the two isomeric components B and C are the active components, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. As a result, this agent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, neomycin induces misreading of the mRNA template and causes translational frameshift, thereby results in premature termination. This eventually leads to bacterial cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-34B2-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-34CB-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Nalidixic Acid","valueDescription":"Nalidixic Acid","ValueMeaning":{"publicId":"3874330","version":"1","preferredName":"Nalidixic Acid","longName":"3874330","preferredDefinition":"A synthetic quinolone and antibacterial agent with urinary tract antiseptic activity. Nalidixic acid concentrates in the renal tubules and bladder and exerts its local antibacterial actions by interference of DNA gyrase activity, thereby inhibiting DNA synthesis during bacterial replication in a dose-dependent manner. Nalidixic acid is active against most gram-negative organisms that cause urinary tract infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nalidixic Acid","conceptCode":"C47630","definition":"A synthetic quinolone and antibacterial agent with urinary tract antiseptic activity. Nalidixic acid concentrates in the renal tubules and bladder and exerts its local antibacterial actions by interference of DNA gyrase activity, thereby inhibiting DNA synthesis during bacterial replication in a dose-dependent manner. Nalidixic acid is active against most gram-negative organisms that cause urinary tract infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-34D8-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-34F1-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Kanamycin","valueDescription":"Kanamycin","ValueMeaning":{"publicId":"3874332","version":"1","preferredName":"Kanamycin","longName":"3874332","preferredDefinition":"An aminoglycoside antibiotic with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically in contact with 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and, misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used for treatment of E. coli, Proteus species (both indole-positive and indole-negative), E. aerogenes, K. pneumoniae, S. marcescens, and Acinetobacter species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kanamycin","conceptCode":"C65997","definition":"An aminoglycoside antibiotic with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically in contact with 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and, misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used for treatment of E. coli, Proteus species (both indole-positive and indole-negative), E. aerogenes, K. pneumoniae, S. marcescens, and Acinetobacter species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-34FE-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-3517-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Fosfomycin","valueDescription":"Fosfomycin","ValueMeaning":{"publicId":"3874334","version":"1","preferredName":"Fosfomycin","longName":"3874334","preferredDefinition":"A phosphoenolpyruvate analogue and a synthetic broad-spectrum antibiotic with antimicrobial and bactericidal properties. Fosfomycin binds to and inactivates the enzyme enolpyruvate transferase. This leads to an irreversible blockage of the condensation of uridine diphosphate-N-acetylglucosamine with p-enolpyruvate, which is one of the first steps of bacterial cell wall synthesis, thereby eventually causing cell lysis and bacterial cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fosfomycin","conceptCode":"C61772","definition":"A phosphoenolpyruvate analogue and a synthetic broad-spectrum antibiotic with antimicrobial and bactericidal properties. Fosfomycin binds to and inactivates the enzyme enolpyruvate transferase. This leads to an irreversible blockage of the condensation of uridine diphosphate-N-acetylglucosamine with p-enolpyruvate, which is one of the first steps of bacterial cell wall synthesis, thereby eventually causing cell lysis and bacterial cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-3524-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-353D-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Chloramphenicol","valueDescription":"Chloramphenicol","ValueMeaning":{"publicId":"3874336","version":"1","preferredName":"Chloramphenicol","longName":"3874336","preferredDefinition":"A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chloramphenicol","conceptCode":"C363","definition":"A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-354A-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-3563-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Cefixime","valueDescription":"Cefixime","ValueMeaning":{"publicId":"3690094","version":"1","preferredName":"Cefixime","longName":"3690094","preferredDefinition":"A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefixime","conceptCode":"C1100","definition":"A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3D79-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-356D-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Trimethoprim","valueDescription":"Trimethoprim","ValueMeaning":{"publicId":"3874338","version":"1","preferredName":"Trimethoprim","longName":"3874338","preferredDefinition":"A synthetic derivative of trimethoxybenzyl-pyrimidine with antibacterial and antiprotozoal properties.  As a pyrimidine inhibitor of bacterial dihydrofolate reductase, trimethoprim binds tightly to the bacterial enzyme, blocking the production of tetrahydrofolic acid from dihydrofolic acid.  The antibacterial activity of this agent is potentiated by sulfonamides. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim","conceptCode":"C908","definition":"A synthetic derivative of trimethoxybenzyl-pyrimidine with antibacterial and antiprotozoal properties.  As a pyrimidine inhibitor of bacterial dihydrofolate reductase, trimethoprim binds tightly to the bacterial enzyme, blocking the production of tetrahydrofolic acid from dihydrofolic acid.  The antibacterial activity of this agent is potentiated by sulfonamides. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-357B-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E591CA67-3594-9D51-E040-BB89AD4371CB","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Doxycycline","valueDescription":"Doxycycline","ValueMeaning":{"publicId":"3874894","version":"1","preferredName":"Doxycycline","longName":"3874894","preferredDefinition":"A synthetic tetracycline derivative exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline","conceptCode":"C457","definition":"A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E595BB41-EE07-FBF1-E040-BB89AD435381","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E595BB41-EE20-FBF1-E040-BB89AD435381","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"ONEDATA","dateModified":"2013-09-04","deletedIndicator":"No"},{"value":"Ceftaroline Fosamil","valueDescription":null,"ValueMeaning":{"publicId":"7295348","version":"1","preferredName":"Ceftaroline Fosamil","longName":"7295348","preferredDefinition":"An N-phosphono prodrug of the fifth-generation cephalosporin derivative ceftaroline with antibacterial activity. Ceftaroline fosamil is hydrolyzed to the active form ceftaroline in vivo. Ceftaroline binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceftaroline Fosamil","conceptCode":"C81034","definition":"An N-phosphono prodrug of the fifth-generation cephalosporin derivative ceftaroline with antibacterial activity. Ceftaroline fosamil is hydrolyzed to the active form ceftaroline in vivo. Ceftaroline binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5A16EF7-9178-0714-E053-F662850AC2F8","latestVersionIndicator":"Yes","beginDate":"2020-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-05-14","modifiedBy":"GDEEN","dateModified":"2023-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B77B7CE-C3C1-5CDD-E063-731AD00AD790","beginDate":"2023-12-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-01","modifiedBy":"GDEEN","dateModified":"2023-12-01","deletedIndicator":"No"},{"value":"Fidaxomicin","valueDescription":null,"ValueMeaning":{"publicId":"6199955","version":"1","preferredName":"Fidaxomicin","longName":"6199955","preferredDefinition":"A narrow-spectrum, 18-membered macrolide antibiotic isolated from the actinomycete Dactylosporangium aurantiacum subsp. hamdenensis with potential antibacterial activity. Although the exact mechanism of action has yet to be fully elucidated, fidaxomicin may bind to and inhibit bacterial DNA-dependent RNA polymerase, thereby inhibiting the initiation of bacterial RNA synthesis. When orally administered, this agent is minimally absorbed into the systemic circulation, acting locally in the gastrointestinal tract. Fidaxomicin appears to be active against pathogenic Gram-positive bacteria, such as clostridia, enterococci, and staphylococci, but does not appear to be active against other beneficial intestinal bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fidaxomicin","conceptCode":"C66979","definition":"A narrow-spectrum, 18-membered macrolide antibiotic isolated from the actinomycete Dactylosporangium aurantiacum subsp. hamdenensis with potential antibacterial activity. Although the exact mechanism of action has yet to be fully elucidated, fidaxomicin may bind to and inhibit bacterial DNA-dependent RNA polymerase, thereby inhibiting the initiation of bacterial RNA synthesis. When orally administered, this agent is minimally absorbed into the systemic circulation, acting locally in the gastrointestinal tract. Fidaxomicin appears to be active against pathogenic Gram-positive bacteria, such as clostridia, enterococci, and staphylococci, but does not appear to be active against other beneficial intestinal bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FD98C0-8FDB-2C45-E053-F662850AF23F","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BF1334A-44B1-4FCD-E063-731AD00A0D19","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Tedizolid Phosphate","valueDescription":null,"ValueMeaning":{"publicId":"14652334","version":"1","preferredName":"Tedizolid Phosphate (Sivextro)","longName":"14652334v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tedizolid Phosphate","conceptCode":"C152537","definition":"The phosphate salt form of tedizolid, an antibacterial agent of the oxazolidinone class, that is used for the treatment of acute bacterial skin and skin structure infections caused by certain Gram-positive microorganisms. Upon intravenous administration, tedizolid targets and binds to the 50S subunit of the bacterial ribosome. This inhibits bacterial protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C06C04E-F0B3-4907-E063-731AD00A8C6E","latestVersionIndicator":"Yes","beginDate":"2023-12-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-08","modifiedBy":"GDEEN","dateModified":"2023-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0C06C04E-F0B4-4907-E063-731AD00A8C6E","beginDate":"2023-12-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-08","modifiedBy":"GDEEN","dateModified":"2023-12-08","deletedIndicator":"No"},{"value":"Dalbavancin","valueDescription":null,"ValueMeaning":{"publicId":"14652335","version":"1","preferredName":"Dalbavancin","longName":"14652335v1.00","preferredDefinition":"A second-generation, semi-synthetic lipoglycopeptide antibiotic, with bactericidal activity against a variety of gram-positive bacteria. Upon administration, dalbavancin binds, at a site different from that of penicillins and cephalosporins, tightly to the D-alanyl-D-alanine portion of peptidoglycan chains, thereby preventing peptidoglycan elongation and interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins and induces cell wall lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dalbavancin","conceptCode":"C116741","definition":"A second-generation, semi-synthetic lipoglycopeptide antibiotic, with bactericidal activity against a variety of gram-positive bacteria. Upon administration, dalbavancin binds, at a site different from that of penicillins and cephalosporins, tightly to the D-alanyl-D-alanine portion of peptidoglycan chains, thereby preventing peptidoglycan elongation and interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins and induces cell wall lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C06D07D-385D-4B82-E063-731AD00AA616","latestVersionIndicator":"Yes","beginDate":"2023-12-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-08","modifiedBy":"GDEEN","dateModified":"2023-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0C06D07D-385E-4B82-E063-731AD00AA616","beginDate":"2023-12-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-08","modifiedBy":"GDEEN","dateModified":"2023-12-08","deletedIndicator":"No"},{"value":"Pyrazinamide","valueDescription":null,"ValueMeaning":{"publicId":"3379510","version":"1","preferredName":"Pyrazinamide","longName":"3379510","preferredDefinition":"A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyrazinamide","conceptCode":"C29395","definition":"A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92A1160-3554-5002-E040-BB89AD4338DD","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D95A00F-42E5-295B-E063-731AD00A149D","beginDate":"2023-12-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-28","modifiedBy":"GDEEN","dateModified":"2023-12-28","deletedIndicator":"No"},{"value":"Nitazoxanide","valueDescription":null,"ValueMeaning":{"publicId":"3944878","version":"1","preferredName":"Nitazoxanide","longName":"3944878","preferredDefinition":"A synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, which is essential to anaerobic energy metabolism. PFOR enzyme reduces nitazoxanide, thereby impairing the energy metabolism. However, interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. Nitazoxanide is active against Giardia lamblia and Cryptosporidium parvum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitazoxanide","conceptCode":"C47637","definition":"A synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, which is essential to anaerobic energy metabolism. PFOR enzyme reduces nitazoxanide, thereby impairing the energy metabolism. However, interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. Nitazoxanide is active against Giardia lamblia and Cryptosporidium parvum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F0FE-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9BBDBF-AB30-712E-E063-731AD00A5C8C","beginDate":"2023-12-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-28","modifiedBy":"GDEEN","dateModified":"2023-12-28","deletedIndicator":"No"},{"value":"Nirmatrelvir/Ritonavir","valueDescription":null,"ValueMeaning":{"publicId":"14667271","version":"1","preferredName":"Nirmatrelvir/Ritonavir (Paxlovid)","longName":"14667271v1.00","preferredDefinition":"A fixed combination of nirmatrelvir, an inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro; 3C-like protease; 3CL protease; 3CLpro; nsp5 protease), and ritonavir, an inhibitor of cytochrome P450 3A4 (CYP3A4), that may be used to treat coronavirus disease 2019 (COVID-19). Upon oral administration of nirmatrelvir/ritonavir, nirmatrelvir selectively targets, binds to, and inhibits the activity of SARS-CoV-2 Mpro. This inhibits the proteolytic cleavage of viral polyproteins, thereby inhibiting the formation of viral proteins including helicase, single-stranded-RNA-binding protein, RNA-dependent RNA polymerase, 20-O-ribose methyltransferase, endoribonuclease and exoribonuclease. This prevents viral transcription and replication. Ritonavir inhibits CYP3A4-mediated metabolism of nirmatrelvir, thereby increasing the plasma concentration of nirmatrelvir.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nirmatrelvir/Ritonavir","conceptCode":"C188303","definition":"A fixed combination of nirmatrelvir, an inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro; 3C-like protease; 3CL protease; 3CLpro; nsp5 protease), and ritonavir, an inhibitor of cytochrome P450 3A4 (CYP3A4), that may be used to treat coronavirus disease 2019 (COVID-19). Upon oral administration of nirmatrelvir/ritonavir, nirmatrelvir selectively targets, binds to, and inhibits the activity of SARS-CoV-2 Mpro. This inhibits the proteolytic cleavage of viral polyproteins, thereby inhibiting the formation of viral proteins including helicase, single-stranded-RNA-binding protein, RNA-dependent RNA polymerase, 20-O-ribose methyltransferase, endoribonuclease and exoribonuclease. This prevents viral transcription and replication. Ritonavir inhibits CYP3A4-mediated metabolism of nirmatrelvir, thereby increasing the plasma concentration of nirmatrelvir.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0DA943A8-D6A5-78C4-E063-731AD00A49B5","latestVersionIndicator":"Yes","beginDate":"2023-12-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-29","modifiedBy":"GDEEN","dateModified":"2023-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0DA943A8-D6A6-78C4-E063-731AD00A49B5","beginDate":"2023-12-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-29","modifiedBy":"GDEEN","dateModified":"2023-12-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261898","version":"1","preferredName":"Text Name","preferredDefinition":"Text; the words of something written.:The words or language units by which a thing is known.","longName":"C25704:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBDEE8CB-7C8A-5E8A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"ONEDATA","dateModified":"2005-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"019C7266-B6D8-0AAA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"GDEEN","dateModified":"2023-12-29","changeDescription":"Version expands max field length to 45 characters","administrativeNotes":"2023.8.28 Updated PV defs for 'No Value Exists'. ak 07.29.22_Appended _1 to SN due to duplicate VD_ghd","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811686","version":"1","longName":"CTMSv3.02","context":"CCR"},{"publicId":"3248617","version":"1","longName":"CCR 2011 Template","context":"CCR"},{"publicId":"3248631","version":"1","longName":"Infection Episode","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2857175","version":"1","longName":"C3D Adopter CDEs for Reuse","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812490","version":"1","longName":"CTMS 3.12B","context":"CCR"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"TX","type":"C3D Name","context":"CCR"},{"name":"INFEC_TX_AGT_NM","type":"USED_BY","context":"NCIP"},{"name":"CTEP","type":"USED_BY","context":"CTEP"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Treatment","type":"Preferred Question Text","description":"Treatment","url":null,"context":"CCR"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Type of antibiotic, antifungals, or non-absorbable gut decontamination received:","url":null,"context":"CTEP"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Specify agents:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"019C7266-B767-0AAA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-09-27","modifiedBy":"CHANGP","dateModified":"2017-03-07","changeDescription":"Includes expanded max field length.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}